Alison gets great relief from Psilocybin found in various types of “Magic Mushrooms” …
Important Update from TheraPsil
Dear Friends of TheraPsil, the Government of Canada and the Canadian Public,
At TheraPsil, our primary mission is to help Canadians in medical need, access psilocybin therapy. Since August 4th, 2020, we have successfully supported 13 individuals across Canada who are now legally allowed to access psilocybin therapy through section 56 exemptions.
While TheraPsil has been focused on advocating for Palliative Canadians, we have also, unofficially, begun advocating to help a broader class of patients such as those who struggle with psychological trauma that can often cause symptoms such as depression and anxiety.
On October 4th, 2020, the first non-palliative Canadian was granted access to psilocybin by way of a section 56 exemption, to treat her unresolved trauma. On November 5th, 2020, this patient was successfully treated with psilocybin therapy by psychotherapist, TheraPsil’s founder, Dr. Bruce Tobin.
“Everyone has trauma, some experience it when we are small and absorb it and it sits in us as we mature into adults. Because of the traumas of my past, I have struggled with anxiety, depression, and addiction for years. During my psilocybin therapy, I went deep, way back to when I was a little girl, and all those things that happened to me. All the unresolved trauma, it came back and I was beyond terrified, shaking uncontrollably and crying, however with my therapist Dr. Tobin, I conquered those tough memories and after a while I realized…. I ain’t scared of Jack S**t….For the first time, I feel like I have won the battle in my mind and my anxiety and depression seem to be gone. The memories are not, but now I know they can’t hurt me.”
– Mona Streleaff, British Columbia, Canada’s First Non-Palliative Canadian to Access Legal Psilocybin Therapy
Mona’s exemption represents a historic moment in Canada and a groundbreaking progressive decision by Health Canada to broaden the class of patients who can access this treatment option, thus further enshrining the rights of Canadians.
While this is excellent news and represents a wealth of opportunities for the future of mental healthcare in Canada, it also represents an equal amount of challenges. TheraPsil has been backed-up with requests for support from patients, both palliative and non-palliative, since the initial August 4th decision, who are seeking access to legal psilocybin therapy. As a small, non-profit organization we need support to keep up with the anticipated increase in patient demand so we can facilitate an expanded mandate that upholds our high standards and protects the integrity of our process.
As such, in response to Health Canada’s groundbreaking decision to grant a section 56 exemption for one non-palliative individual, TheraPsil is seeking to fundraise. We will soon be launching a GoFundMe campaign with a goal to raise $250’000. We have already secured a generous donor who is willing to match with an additional $250’000 to reach our initial fundraising goal of $500’000, by December 31, 2020.
Part of the support we need is human resources and this is where we plan to dedicate most of the funds raised. We need nurses and physicians who can triage patients to ensure we are facilitating safe and equitable access to legal psilocybin therapy. We also need funding to help complete and launch our psilocybin therapy training program for Canadian clinicians, with an aim to roll out this program by January 1st 2021. If we are successful in our current advocacy campaign, clinicians and healthcare professionals will be granted section 56 exemptions by the end of this month, for training purposes. TheraPsil’s training program aims to be the first legal training program in Canada to offer experiential training – where trainees take psilocybin mushrooms and enter this non-ordinary state of consciousness first-hand.
Although one non-palliative individual has been granted access to psilocybin therapy, and we have been eager to share this with you all, we must be transparent about our current bandwidth and ability to support more non-palliative individuals, like Mona, at this time.
Unfortunately, at the current moment, we do not have the resources to broaden our inclusion criteria, and for the near future, we will remain open to only supporting palliative Canadians, those with a terminal illness or those in remission from a life-threatening illness (i.e Cancer survivors) who suffer from end-of-life distress, as our website indicates. We are a patient-first organization and in order to maintain the integrity of our process and maintain the high standards of support we provide to patients, we must ensure we expand our services in accordance with our means and ability to provide safe and equitable care.
However, rest assured, our full intention is that through meeting our fundraising goal, we will soon be able to announce new patient inclusion criteria and broaden access so we can support more Canadians, like Mona, who suffer from complex trauma and various mental health conditions and symptoms.
We are so grateful for the support of the psychedelic community, the Federal Government, many Canadian MP’s, the patients we have supported, our small but mighty clinical and operations team, and the hundreds of Canadians who have advocated alongside us. Your support has allowed us to get this far and there is so much work to still be done! Every small step forward and every patient who is granted an exemption, is a win for compassionate access and we are deeply dedicated to continuing the pursuit of our four pillar mission, for the benefit of all Canadians:
COMPASSIONATE ACCESS: Establish safe, compassionate, and legal access to psychedelic-assisted therapy for those in medical need.
PUBLIC EDUCATION: Increase awareness of the general public and health care professionals about the merits and limitations of psychedelic-assisted therapy.
PROFESSIONAL TRAINING: Developing safe, simple, and effective protocols for credentialed health professionals across Canada to deliver psilocybin-assisted therapy, in collaboration with other active organizations.
RESEARCH: Facilitate research and evaluation, in collaboration with Canadian and international partners.
Please stay tuned for updates by following us on Twitter and signing up for our newsletter so you can be informed when we launch our GoFundMe and have broadened our patient inclusion criteria.
If you meet our current criteria, please continue to contact us for support. We are here to help and want to hear from you.
To Psilocybin Therapy,
– Spencer Hawkswell, CEO of TheraPsil & The TheraPsil Coalition
My name is Alison Myrden; I am a retired law enforcement officer, one of Canada’s 1st legally licensed medical cannabis patients from 1994, a global drug law reform activist and the world’s 1st legally authorized medical psilocybin patient for pain (in 2017). Here is a brief look at the journey of my natural health regime over the last 30+ years so that you, too, are informed in all things natural being studied around the world as medicine.
Let us talk Psilocybin – my fight has always been for all of us. Especially for those who choose to consume illicit substances for ANY reason; social, religious, or medical. We all deserve the opportunity to choose. From my experience, psilocybin or magic mushrooms are safer than cannabis; I PROMISE.
My battle for natural medicine began when I was in my early 20s due to the indication of being formally diagnosed with Primary Progressive Multiple Sclerosis at 28 years old. Then, fighting a violent pain located in both the left side of my head and face, which was diagnosed as Cluster Headaches and soon changed to Trigeminal Neuralgia. Described as “The worst pain known to medicine,” for reference on the excruciating scale. A few years later, my diagnosis was again changed, to Bilateral Trigeminal Neuralgia. My pain had then escalated to both sides of my face and head, now occurring 24 hours a day.
By my mid 20s (the 1980s), I was having an exceedingly difficult time finding anything anywhere to give me adequate relief. I had been given every medication known to the Canadian Pharmacopoeia by doctors for my illnesses when I was young and had reached out to doctors / scientists around the world for help being that pills were not helping me manage whatsoever. 32 pills, heroin, cocaine and 2,000mg of morphine daily for almost two decades – all doctor authorized and prescribed. I was consuming substances such as cannabis and psilocybin the entire time over the years, while reducing all those pharmaceuticals and learning with the assistance of doctors and scientists whom I met along the way. This arm’s length guidance taught me how to indulge in these nature-born meds safely and properly; both are extremely important.
Luckily, I also had several college courses under my belt which included pharmacology, anatomy, and physiology. I also acquired knowledge of appropriate harm reduction techniques involving issues of overdose. I started consuming psilocybin over 35 years ago, for fun. This changed quickly as I started taking psilocybin for pain relief because the cannabis, all the pills and everything else I was medicating with at the time were not helping the same way with the violent bouts of pain via my condition at that point. One night, when I just could not take the pain anymore – my girlfriend, the hostess of a party I attended, immediately brought me some “special” tea.
Little did I know, that was my 1st experience using psilocybin for the brutal neurological pain I was experiencing; the pain was astonishingly gone in minutes. I am living proof that macrodosing does indeed work! The energy psilocybin delivered to my body was unreal, no wonder they call the compound “magic,”. I will never forget the day I was at a federally licensed cannabis patient’s home when the vicious pain in my face came washing over. As luck would have it, this patient offered me 5 grams of “Blue Cambodian” psilocybin mushrooms. I ate all 5 grams and somehow, my pain was completely gone for the first time EVER – for almost five hours.
I was so desperate for relief and knew already the lethal overdose and toxicity levels were the lowest for psilocybin than for any other illicit substance. I returned to my neurologist the following week for “the world’s 1st authorization of psilocybin for excruciating pain” treatment ~ drinking and/or eating 50-60 grams of dried psilocybin a day; from April 3rd, 2017 til today. From my original consumption of 1 to 2 grams of dried psilocybin in tea and chocolate to 5 grams of dried psilocybin every two hours, the last 32 years has led me on a very magical journey.
Remember…I have had this silly pain 24 hours a day for over thirty years until 2017, when psilocybin changed my life for the better!”
Retired Law Enforcement Officer
Global Drug Law Reform Activist
Federal Medical Cannabis Exemptee in Canada since 1994 http://www.AlisonMyrden.com/
Canadian Patient Representative for the IACM
International Association for Cannabinoid Medicines http://www.cannabis-med.org/
NDP Candidate for Oakville, Ontario 2004
New Democratic Party of Canada http://www.ndp.ca/
UC Berkeley launches new center for psychedelic science and education
Yasmin Anwar –
Fifty years after political and cultural winds slammed shut the doors on psychedelic research, UC Berkeley is making up for lost time by launching the campus’s first center for psychedelic science and public education.
With $1.25 million in seed funding from an anonymous donor, the new UC Berkeley Center for the Science of Psychedelics will conduct research using psychedelics to investigate cognition, perception and emotion and their biological bases in the human brain.
The center is also developing a program for educating the public about this rapidly advancing field of research. Initial experimental studies will use psilocybin, the principal psychoactive compound in magic mushrooms.
“There’s never been a better time to start a center like this,” said UC Berkeley neuroscientist David Presti, one of the center’s founding members. “The renewal of basic and clinical science with psychedelics has catalyzed interest among many people.”
“We’re really interested in what psychedelics can teach us about consciousness, perception, creativity and learning,” said Pollan, who felt compelled to explore psychedelics in late middle age, instead of in his youth, and write about them.Other acclaimed co-founders of the center include psychologist Dacher Keltner, who studies the mental and physiological benefits of awe, and journalism professor Michael Pollan, whose 2018 bestseller, How to Change Your Mind: What the New Science of Psychedelics Teaches Us About Consciousness, Dying, Addiction, Depression and Transcendence, was one of the inspirations for the center.
“Psychedelics have a particular value later in life, because that is when you are most stuck in your patterns. They give you the ability to shake them loose,” he said.
The minds they are a-changin’
Research at the new center will complement ongoing clinical studies at other institutions — such as Johns Hopkins University in Maryland and Imperial College London — that are integrating psilocybin and other psychedelic compounds with psychotherapy to treat mental disorders, such as anxiety, depression, post-traumatic stress disorder and substance abuse.
“Some of these studies have produced striking results in cases that are otherwise resistant to more conventional medical treatment. This suggests that psychedelic compounds may offer new hope for people suffering from these disorders,” said UC Berkeley neuroscientist Michael Silver, inaugural director of the UC Berkeley Center for the Science of Psychedelics.
Yet, much remains unknown about the brain mechanisms behind the efficacy of psychedelic compounds in treating mental health disorders. Also poorly understood is the ability of these compounds to improve cognitive flexibility, alter visual perception, engender feelings of awe and change patterns of brain activity.
Addressing these questions will be a major part of the research at the UC Berkeley Center for the Science of Psychedelics, which will focus on healthy study participants, Silver said.
Over time, and with more funding, Silver’s hope is that researchers at Berkeley and other institutions will study psychedelics as part of the center’s activities not just in relation to psychology and neuroscience, but also philosophy, religion, anthropology, art, and even computer science and artificial intelligence.
“This is a pivotal time in history for a discussion about psychedelics and under what circumstances they should be used,” he said. “This has obviously been a very polarizing topic, but I think people’s minds are changing.”
Training psychedelic guides
One unique aspect of the new center is its emphasis on public education. It will produce a website offering rigorously vetted original and curated content covering scientific, political, business and cultural developments in psychedelics, Pollan said.
The center’s plan to explore ways of supporting healthy volunteer research participants as they undergo psychedelic experiences in the center’s studies is unique, too.
To do this, the center plans to collaborate with the Graduate Theological Union, an independent consortium of religious schools and theological institutes based in Berkeley and the larger San Francisco Bay Area, in the development of an immersive learning program on psychedelics and spirituality.
This program will eventually train guides, also known as facilitators, in the cultural, contemplative and spiritual care dimensions of psychedelics, working in partnership with the UC Berkeley Center for the Science of Psychedelics research studies. Given the rapidly growing number of psychedelic research studies, there are not enough trained facilitators to meet the demand, the center’s founders said.
“The training of facilitators is an indispensable part of this project,” said Sam Shonkoff, an assistant professor of Jewish studies at the Graduate Theological Union who is collaborating with the center.
Brian Anderson, a UCSF psychiatrist, and Celina De Leon, who has a master’s degree in divinity from the Graduate Theological Union, both have expertise in the ritual use of psychedelic plants and are involved in creating an immersive learning program for research participants and designing the training program.
Ancient healing precedes modern science
While hallucinogenic plants and fungi have been used for millennia in ceremonial rituals, they were not known to Western medical science until the late 19th century.
In 1938, Swiss chemist Albert Hofmann synthesized lysergic acid diethylamide (LSD) while investigating potential new pharmaceutical medications, and he discovered LSD’s mind-altering effects in 1943. Samples were sent to medical centers and universities worldwide to promote research into its possible benefits.
In 1966, states began to ban hallucinogens, and when the Federal Controlled Substances Act was implemented in 1971, LSD and other psychedelic drugs were classified as Schedule I controlled substances, and studies of their use in human subjects essentially ground to a halt that lasted until the recent renaissance.
“Together with societal changes during the 1960s, psychedelic drugs made people ask questions about the status quo and were seen as a destabilizing force, and the backlash to that suppressed psychedelic research with human subjects for decades,” Silver said.
More recently, psilocybin, LSD and dimethyltryptamine, a key psychoactive component of the ayahuasca brew, have received renewed attention, both in research settings and in society at large, along with MDMA (ecstasy) and ketamine.
Future investigations will include studying the neural mechanisms of visual hallucinations to better understand how the brain constructs our perception of the world around us, comparing psychedelic and non-psychedelic mystical-type experiences and measuring the long-lasting effects of psychedelic experiences on social and political attitudes, identity and resilience to stress.At the center, researchers will focus on the use of these ancient compounds to explore the unplumbed depths of the mind and to shed light on how these molecules can improve mental health.
“Psychedelic medicines can open a doorway to seeing one’s psyche and connection with the world in new and helpful ways,” Presti said. “That’s been appreciated by shamanic traditions for thousands of years. Science is now exploring new ways to investigate this.”
Psilocybin Sessions: Psychedelics could help people with addiction and anxiety
Anderson Cooper – August 16, 2020
Study participants at some of the country’s leading medical research centers are going through intense therapy and six-hour psychedelic journeys deep into their minds to do things like quit smoking and worry less.
For most of us, psychedelic drugs conjure up images of the 1960’s – hippies tripping out on LSD or magic mushrooms. But, as we reported last fall, these powerful, mind-altering substances are now being studied seriously by scientists inside some of the country’s foremost medical research centers. They’re being used to treat depression, anxiety and addiction…
And early results are impressive, as are the experiences of the studies’ volunteers who go on a six-hour, sometimes terrifying, but often life-changing psychedelic journey deep into their own minds.
Carine McLaughlin: (LAUGH) People ask me, “Do you wanna do it again?” I say, “Hell no. I don’t wanna go do that again.”
Anderson Cooper: It was really that bad?
Carine McLaughlin: Oh, it was awful. The entire time, other than the very end and the very beginning, I was crying.
Carine McLaughlin is talking about the hallucinogenic experience she had here at Johns Hopkins University, after being given a large dose of psilocybin, the psychedelic agent in magic mushrooms, as part of an ongoing clinical trial.
Roland Griffiths: We tell people that their experiences may vary from very positive to transcendent and lovely to literally hell realm experiences.
Anderson Cooper: Hell realm?
Roland Griffiths: As frightening an experience as you have ever had in your life.
That’s scientist Roland Griffiths. For nearly two decades now, he and his colleague Matthew Johnson have been giving what they call “heroic doses” of psilocybin to more than 350 volunteers, many struggling with addiction, depression and anxiety.
Anderson Cooper: Can you tell who is going to have a bad experience, who’s gonna have a transcendent experience?
Roland Griffiths: Our ability to predict that is almost none at all.
Anderson Cooper: Really?
Matthew Johnson: About a third will– at our– at a high dose say that they have something like that, what folks would call a bad trip. But most of those folks will actually say that that was key to the experience.
Carine McLaughlin was a smoker for 46 years and said she tried everything to quit before being given psilocybin at Johns Hopkins last year. Psilocybin itself is non-addictive.
Anderson Cooper: Do you remember what, like, specifically what you were seeing or?
Carine McLaughlin: Yes. The ceiling of this room were clouds, like, heavy rain clouds. And gradually they were lowering. And I thought I was gonna suffocate from the clouds.
That was more than a year ago; she says she hasn’t smoked since. The study she took part in is still ongoing, but in an earlier, small study of just 15 long-term smokers, 80% had quit six months after taking psilocybin. That’s double the rate of any over-the-counter smoking cessation product.
Roland Griffiths: They come to a profound shift of world view. And essentially, a shift in sense of self that I think–
Anderson Cooper: They– they see their life in a different way?
Roland Griffiths: Their world view changes and– and they are less identified with that self-narrative. People might use the term “ego.” And that creates this sense of freedom.
And not just with smokers.
Jon Kostakopoulos: Beer usually, cocktails, usually vodka sodas, tequila sodas, scotch and sodas.
Jon Kostakopoulos was drinking a staggering 20 cocktails a night and had been warned he was slowly killing himself when he decided to enroll in another psilocybin trial at New York University. During one psilocybin session, he was flooded with powerful feelings and images from his past.
Jon Kostakopoulos: Stuff would come up that I haven’t thought of since they happened.
Anderson Cooper: So old memories that you hadn’t even remembered came back to you?
Jon Kostakopoulos: I felt, you know, a lot of shame and embarrassment throughout one of the sessions about my drinking and how bad I felt for my parents to put up with all this.
He took psilocybin in 2016. He says he hasn’t had a drink since.
Anderson Cooper: Do you ever have a day where you wake up and you’re like, man, I wish I could have a vodka right now or beer?
Jon Kostakopoulos: Never.
Anderson Cooper: Not at all?
Jon Kostakopoulos: Not at all, which is the craziest thing because that was my favorite thing to do.
Using psychedelic drugs in therapy is not new. There were hundreds of scientific studies done on a similar compound – LSD – in the 1950’s and 60’s. It was tested on more than 40,000 people, some in controlled therapeutic settings like this one. But there were also abuses. The U.S. military and CIA experimented with LSD sometimes without patients knowledge.
Fear over rampant drug use and the spread of the counterculture movement, not to mention Harvard professor Timothy Leary urging people to turn on, tune in and drop out, led to a clamp down.
In 1970, President Richard Nixon signed the controlled substances act and nearly all scientific research in the U.S. Into the effects of psychedelics on people stopped. It wasn’t until 2000 that scientist Roland Griffiths won FDA approval to study psilocybin.
Roland Griffiths: This whole area of research has been in the deep freeze for 25 or 30 years. And so as a scientist, sometimes I feel like Rip Van Winkle.
Anderson Cooper: And once you saw the results…
Roland Griffiths: Yeah. The red light started flashing. This is extraordinarily interesting. It’s unprecedented and the capacity of the human organism to change. It just was astounding.
Anderson Cooper: It sounds like you are endorsing this for everybody.
Roland Griffiths: Yeah, let’s be really clear on that. We are very aware of the risks, and would not recommend that people simply go out and do this.
Griffiths and Johnson screen out people with psychotic disorders or with close relatives who have had schizophrenia or bipolar disorder. Study volunteers at Johns Hopkins are given weeks of intensive counseling before and after the six-hour psilocybin experience; the psilocybin is given in a carefully controlled setting one to three times. To date, they say there’s not been a single serious adverse outcome.
We were told we couldn’t record anyone participating in the study while they were on psilocybin because it might impact their experience, but we were shown how it begins – without the psilocybin.
You lay on a couch, with a blindfold to shut out distractions and headphones playing a mix of choral and classical music – a psychedelic soundtrack with a trained guide, mary cosimano, watching over you.
Everything is done the same way it was for the LSD experiments scientists conducted in the 1950s and 60s. Some of the most dramatic results have been with terminal cancer patients struggling with anxiety and paralyzing depression.
Kerry Pappas: I start seeing the colors and the geometric designs and it’s like ‘oh this is so cool, and how lovely’ and, and then, boom. Visions began.
Kerry Pappas was diagnosed with stage III lung cancer in 2013. During her psilocybin session, she found herself trapped in a nightmare her mind created.
Kerry Pappas: An ancient, prehistoric, barren land. And there’s these men with pickaxes, just slamming on the rocks. So…
Anderson Cooper: And this felt absolutely real to you?
Kerry Pappas: Absolutely real. I was being shown the truth of reality. Life is meaningless, we have no purpose. And then I look and I’m still like a witness, a beautiful, shimmering, bright jewel. And then it was sound, and it was booming, booming, booming. Right here right now.
Anderson Cooper: That was being said?
Kerry Pappas: Yes. “You are alive. Right here right now, because that’s all you have.” And that is my mantra to this day.
Michael Pollan: It seemed so implausible to me that a single experience caused by a molecule, right, ingested in your body could transform your outlook on something as profound as death. That’s– that’s kind of amazing.
Author Michael Pollan wrote about the psilocybin studies in a bestselling book called “How to Change Your Mind.” As part of his research, he tried psilocybin himself with the help of an underground guide.
Anderson Cooper: The kind of things that cancer patients were saying, like, “I touched the face of God.” You were skeptical about when you hear phrases like that?
Michael Pollan: Yeah. Or, “Love is the most important thing in the universe.” When someone tells me that I’m just like, “yeah, okay.”
Anderson Cooper: So you don’t go for some of the phrases that are used?
Michael Pollan: No. It gives me the willies as a writer. And I really struggled with that cause during one of my experiences I came to the earth-shattering conclusion that love is the most important thing in the universe. But it’s, that’s Hallmark card stuff, right? And um, so…
Anderson Cooper: And yet while you were on it and afterward…
Michael Pollan: It was profoundly true. And it is profoundly true. Guess what? Um…
Anderson Cooper: There’s a reason it’s on a Hallmark card.
Michael Pollan: There is a reason. And one of the things psychedelics do is they peel away all those essentially protective levels of irony and, and cynicism that we, that we acquire as we get older and you’re back to those kind of “Oh, my God. I forgot all about love.” (Laugh)
Pollan said he also experienced what the researchers describe as ego loss, or identity loss – the quieting of the constant voice we all have in our heads.
Michael Pollan: I did have this experience of seeing my ego– burst into– a little cloud of Post-It notes. I know it sounds crazy.
Anderson Cooper: And what are you are without an ego?
Michael Pollan: You’re, uh… (Laugh) You had to be there.
Researchers believe that sensation of identity loss occurs because psilocybin quiets these two areas of the brain that normally communicate with each other. They’re part of a region called the default mode network and it’s especially active when we’re thinking about ourselves and our lives.
Michael Pollan: And it’s where you connect what happens in your life to the story of who you are.
Anderson Cooper: We all develop a story over time about what our past was like and who we are.
Michael Pollan: Right. Yeah, what kind of person we are. How we react. And the fact is that interesting things happen when the self goes quiet in the brain, including this rewiring that happens.
To see that rewiring, Johns Hopkins scientist Matthew Johnson showed us this representational chart of brain activity. The circle on the left shows normal communication between parts of the brain, on the right, what happens on psilocybin. There’s an explosion of connections or crosstalk between areas of the brain that don’t normally communicate.
Anderson Cooper: The difference is just startling.
Matthew Johnson: Right.
Anderson Cooper: Is that why people are having experiences of– seeing you know, repressed memories, or past memories, or people who have died or?
Matthew Johnson: That’s what we think. And even the perceptual effect, sometimes the synesthesia, like, the– the seeing sound.
Anderson Cooper: People see sound?
Matthew Johnson: Yeah, sometimes.
Anderson Cooper: I– I don’t even know what that means.
Matthew Johnson: Right, yeah. (LAUGH) It’s– it’s–
Michael Pollan: Maybe the ego is one character among many in your mind. And you don’t necessarily have to listen to that voice that’s chattering at you and criticizing you and telling you what to do. And that’s very freeing.
It was certainly freeing for Kerry Pappas. Though her cancer has now spread to her brain, her crippling anxiety about death is gone.
Kerry Pappas: Yeah, it’s amazing. I mean, I feel like death doesn’t frighten me. Living doesn’t frighten me. I don’t frighten me. This frightens me.
Anderson Cooper: This interview frightens you, but death doesn’t?
Kerry Pappas: No.
It turns out most of the 51 cancer patients in the Johns Hopkins study experienced “significant decreases in depressed mood and anxiety” after trying psilocybin. Two-thirds of them rated their psilocybin sessions as among the most meaningful experiences of their lives. For some, it was on par with the birth of their children.
Kerry Pappas: To this day, it evolves in me.
Anderson Cooper: It’s still alive in you–
Kerry Pappas: It’s still absolutely alive in me.
Anderson Cooper: Does it make you happier?
Kerry Pappas: Yeah. And– and I don’t necessarily use the word happy.
Kerry Pappas: Comfortable. Like, comfortable. I mean, I’ve suffered from anxiety my whole life. I’m comfortable. That, to me, okay. I can die. I’m comfortable. (LAUGH) I mean, it’s huge. It’s huge.
The first Canadian to legally consume psilocybin for medical purposes shares his experience
“I had some ideas about what I thought I would get out of this, but the actual feelings and experience of it are so much better.”
By Sam Riches – August 21, 2020
On the night that Thomas Hartle became the first Canadian to legally consume psilocybin for medical purposes, Dr. Bruce Tobin, a psychotherapist and professor at the University of Victoria, shared a cab with filmmaker Randall “Peg” Peters.
The two men, along with John Simpson, a hospice companion and sitter, had spent the day with Hartle as he went through his first therapeutic dosing experience in the guest bedroom of his Saskatoon home.
Peters wasn’t sure if what had transpired over the previous six hours was a success. In the cab, he expressed his concerns to Dr. Tobin that perhaps Hartle hadn’t benefited in any significant way, but the doctor reassured him. “It’s like good tea,” he said. “You just need to let it steep.”
That night, back at the Hartle household, Hartle enjoyed the best sleep he’s had since receiving his terminal cancer diagnosis four years ago. In the week that has passed since that dose, Hartle hasn’t had a single anxiety attack, he said, a personal record.
A Saskatoon dad in palliative care is still waiting to find out if he can legally use psilocybin for mental health
Four Canadians receive medical exemptions for psilocybin therapy
Forget taking a pill a day. Canada is using psychedelics to revolutionize the way we treat mental health and addiction
“I have had anxiety for so long, I had sort of forgotten what it feels like to not have it,” Hartle said during a webinar Thursday evening, speaking publicly about his experience for the first time. “To experience the lack of anxiety I have had this week is beyond words. It’s amazing. I have no idea how long this particular benefit will last, but so long as it’s here, it’s really, really amazing and good.”
Hartle, a father of two and an IT professional of 25 years, had never taken psilocybin — a psychedelic drug derived from magic mushrooms — in his life. He previously told The GrowthOp that he was interested in pursuing psilocybin therapy as a means to address the existential anxiety that accompanies living with a terminal diagnosis, something that traditional anti-anxiety medications don’t treat.
Hartle went through several preparatory sessions before consuming the dose, to best learn how the process would work and to form a relationship with the doctors and those involved. “Before this experience, I had some ideas about what I thought I would get out of this, but the actual feelings and experience of it are so much better,” he said during the webinar.
“I would highly recommend that Canadians consider it as an option. The psilocybin, for me, was very gentle and effective. Even if I didn’t have any more effects tomorrow, I would feel very comfortable having another session to boost it back up, and, worst case, that would still be only a single dose once a week — there isn’t any other medication out there that has that sort of efficacy.”
Earlier this month, four Canadians received Section 56 exemption to the Controlled Drugs and Substances Act, allowing them to pursue psilocybin therapy for end-of-life distress. The exemptions were granted by federal health minister Patty Hajdu, and the applications were completed with the help of TheraPsil, a B.C.-based, non-profit organization founded by Dr. Tobin and made up of a coalition of healthcare professions, researchers, advocates and policymakers.
For Dr. Tobin, Hartle’s experience is in line with research about the therapeutic benefits of psychedelics from institutions such as John Hopkins, Yale University and the University of Toronto. Multiple studies indicate that psilocybin can lead to significant and sustained decreases in depression and anxiety in patients with life-threatening cancer.
“A fundamental dynamic in this healing potential of psilocybin is that it allows our ego self to temporarily relax the grip of our negative and pain-producing belief systems, to relax and let go of that grip on our sense of who we are and what’s really important and what living is all about,” Dr. Tobin said. “With this relaxation of old habits of thinking, new perspectives and attitudes and assumptions are possible, leading to new possibilities for being in the world with our disease.”
Even with the four exemptions that have been granted, psilocybin remains a restricted medicine, making it illegal for doctors to use psilocybin as part of their training. Dr. Tobin emphasized that needs to change and that the organization will be working hard in the months ahead to fight for therapists to have legal access to psilocybin for training purposes.
“That (restriction) doesn’t really make any sense to any of us,” Dr. Tobin said during the webinar. “Imagine what it would be like to go to a sex therapist who you know has never had sex.”
Within the next few years, Dr. Tobin said he expects that “the face of Canadian psychiatry and clinical psychology is going to be transformed by these psychedelic medicines.” The organization is encouraging interested Canadians who believe they might benefit from psilocybin therapy to contact them.
Psychiatrist Dr. Crosbie Watler, former chief of psychiatry at Kenora, Ont.’s Lake of the Woods District Hospital, called Hartle’s experience “a call to action.”
“I’ve been despairing because I see the treadmill of care, but I also see that people are not healing in a comprehensive way. This is at a time when we are prescribing more than ever before, so what is missing?”
According to Dr. Watler, the potential to experience a different level of consciousness is a “gift” that psilocybin offers and can lead to lasting changes in patients facing end-of-life distress.
“There is the knowledge of who you are, which we can have at an intellectual level using various talk therapies, but then having the breakthrough of that experience of a different level of consciousness and seeing ourselves and our place in the universe through an entirely different lens, that, to me, is what medicine should be all about — healing, and not just painting the brown leaves green.”
Chronic pain and psychedelics: a review and proposed mechanism of action
May 4, 2020
The development of chronic pain is a complex mechanism that is still not fully understood. Multiple somatic and visceral afferent pain signals, when experienced over time, cause a strengthening of certain neural circuitry through peripheral and central sensitization, resulting in the physical and emotional perceptual chronic pain experience. The mind-altering qualities of psychedelics have been attributed, through serotonin 2A (5-HT2A) receptor agonism, to ‘reset’ areas of functional connectivity (FC) in the brain that play prominent roles in many central neuropathic states. Psychedelic substances have a generally favorable safety profile, especially when compared with opioid analgesics. Clinical evidence to date for their use for chronic pain is limited; however, several studies and reports over the past 50 years have shown potential analgesic benefit in cancer pain, phantom limb pain and cluster headache. While the mechanisms by which the classic psychedelics may provide analgesia are not clear, several possibilities exist given the similarity between 5-HT2A activation pathways of psychedelics and the nociceptive modulation pathways in humans. Additionally, the alterations in FC seen with psychedelic use suggest a way that these agents could help reverse the changes in neural connections seen in chronic pain states. Given the current state of the opioid epidemic and limited efficacy of non-opioid analgesics, it is time to consider further research on psychedelics as analgesics in order to improve the lives of patients with chronic pain conditions.
Keywords: alternative therapies; chronic pain: central pain syndromes, fibromyalgia; chronic pain: neuropathic pain; pain medicine; pharmacology: other.
Canada Will Let Terminally Ill Patients Use Psychedelic Mushrooms For End-Of-Life Care
By Ben Adlin –
Four cancer patients in end-of-life care will be become the first people in decades to legally possess and consume psilocybin mushrooms in Canada after a landmark decision Tuesday by the country’s Ministry of Health.
The patients petitioned Health Minister Patty Hajdu back in April for exemptions from the country’s laws against psilocybin in order to use psychedelic mushrooms as part of psychotherapy treatment. On Tuesday afternoon, Hajdu officially granted the patients’ request, according to the nonprofit TheraPsil, which assisted with the application.
The approvals mark the first publicly-known individuals to receive a legal exemption from the Canadian Drugs and Substances Act to access psychedelic therapy, Therapsil said, and the first medical patients to legally use psilocybin since the compound became illegal in Canada in 1974.
“This is the positive result that is possible when good people show genuine compassion. I’m so grateful that I can move forward with the next step of healing,” one of the patients, Thomas Hartle, said in a statement Tuesday.
Hartle and other patients personally thanked the health minister for what they described as an act of compassion. The applicants, as well as various advocates for psychedelic therapy, had personally appealed to Hajdu via a concerted social media campaign during the months their applications were pending.
In statements issued Tuesday, the patients thanked Hajdu and said they were optimistic that more patients will one day have safe, legal access to psilocybin for therapeutic use.
“I want to thank the Health Minister and Health Canada for approving my request for psilocybin use. The acknowledgement of the pain and anxiety that I have been suffering with means a lot to me, and I am feeling quite emotional today as a result,” said Laurie Brooks, an applicant from British Columbia. “I hope this is just the beginning and that soon all Canadians will be able to access psilocybin, for therapeutic use, to help with the pain they are experiencing, without having to petition the government for months to gain permission.”
TheraPsil said on Tuesday that it expects more patients to petition the government for exemptions following the first four patients’ approval. A separate request by the nonprofit to allow therapists to use psychedelics, was not addressed in Tuesday’s announcement, the group said.
All of the four patients have been diagnosed with untreatable cancer. Therapists who use psychedelics in their practices say that psilocybin-aided therapy sessions can help patients deal with issues such as depression and anxiety, allowing them to better accept death as a natural part of existence.
Health Canada did not immediately respond to Marijuana Moment’s request to confirm the TheraPsil announcement about the approved applications.
“At this point psilocybin is a reasonable medical choice for these individuals,” the group’s executive director, Spencer Hawkswell, told Marijuana Moment in an interview last month. “This is about the minister being compassionate and using her ministerial abilities to help give patients access to something that’s going to help them.”
The therapeutic potential of psychedelics has attracted attention in recent years from a growing number of academics, policy makers and even the U.S. government. In September of last year, Johns Hopkins University announced the launch of the nation’s first-ever psychedelic research center, a $17-million project to study whether psychedelics can treat conditions such as opioid use disorder, Alzheimer’s disease, depression, anxiety and post-traumatic stress disorder.
Meanwhile, activists in the United States have advocated for state- and local-level reforms to research, decriminalize and in some cases even legalize psychedelics.
In May 2019, Denver became the first U.S. city to enact such a reform, with voters approving a measure that effectively decriminalized psilocybin possession. Soon after, officials in Oakland, California, decriminalized possession of all plant- and fungi-based psychedelics. In January of this year, the City Council in Santa Cruz, California, voted to make the enforcement of laws against psychedelics among the city’s lowest enforcement priorities.
Reformers are pushing for similar changes in other jurisdictions. A proposal in Washington, D.C. would allow voters to decide this fall whether to decriminalize plant- and fungi-based psychedelic drugs, including psilocybin, ayahuasca and ibogaine. A decision on whether that initiative will make the ballot is expected later this week. In Oregon, voters in November will consider a measure that would decriminalize all drugs and expand access to treatment. A separate Oregon proposal would legalize psilocybin therapy—the same therapy sought by the Canadian cancer patients.
Pioneering Psychedelic Researcher Once Again Paves the Way with Historic Psilocybin Study for End of Life Patients
BY ANN HARRISON – AUGUST 3, 2020
Amild mannered, bespectacled professor, Dr. Charles S. Grob has been quietly pushing the envelope of psychedelic psychiatry and scholarship for decades.
A Lundquist Institute investigator and Professor of Psychiatry and Bio-Behavioral Sciences at the UCLA School of Medicine, Grob is also the Director of the Division of Child and Adolescent Psychiatry at Harbor-UCLA Medical Center.
Risking his own reputation in the medical community to conduct research that was at one time considered taboo, Grob carried forward the promising studies of the 1960’s and 1970’s which suggested that psychedelic substances had the potential to reduce the pain and anxiety of people approaching death.
Working in a modest office on the grounds of a county hospital in Los Angeles where he runs a mental health clinic for children and adolescents, Grob stepped up to continue meticulous clinical investigations to study the safety and feasibility of psychedelic medications.
Grob and his colleagues at the Harbor-UCLA Medical Center conducted pioneering research into the use of psilocybin as a mental health treatment for terminally ill cancer patients. Published in 2011 in the Archives of General Psychiatry, their Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer was the first to show that psilocybin had a dramatic effect on the existential distress of people nearing death, improving their quality of life and offering psychospiritual epiphanies.
This early pilot study pointed the way for two following groundbreaking clinical trials published in 2016 that showed the promise of psychedelics to relieve emotional suffering at the end of life.
One set of clinical trials was led by Anthony P. Bossis, PhD, Clinical Assistant Professor of Psychiatry at New York University School of Medicine, and his fellow researchers at New York University. The second was carried out by Dr. Roland Griffiths and a team of researchers at Johns Hopkins University. Both investigations showed that psilocybin reduced anxiety and depression for patients with terminal cancer.
Grob is now practicing telemedicine due to the Covid-19 pandemic, but he and his fellow investigators continue the quest for a deeper understanding of how psychedelics can support people at the end of life.
The Lundquist Institute for Biomedical Innovation announced last month that Grob and Bossis will lead a new multi-site clinical trial to study the effectiveness and safety of psilocybin to treat terminally ill people with psychological distress.
The new clinical trial will be funded by an anonymous $1.75 million donation to The Lundquist Institute. The funds will also be used to develop education and outreach programs on the use of psilocybin for palliative care, a medical specialty that focuses on relieving suffering and improving the quality of life for people with a serious illness.
The Lundquist Institute study will be the first to investigate a psychedelic substance for palliative care and the first to conduct new clinical trials to move the findings of the 2016 trials forward. This research comes at a critical time as a wave of emerging companies and organizations are investigating the use of psychedelics for mental health treatments.
“We don’t die well in America and have few approaches to relieve end-of-life emotional suffering,” says Bossis in a statement from The Lundquist Institute. “Clinical research has demonstrated that psychedelic-generated mystical experience dramatically reduces depression, anxiety, and demoralization in end-of-life existential distress and can improve quality of life and a sense of personal meaning.”
Founded in 1952, the Torrance-CA-based nonprofit Lundquist Institute, supports more than 120 principal investigators working on over 1,000 research studies. The Lundquist Institute created the training for and coined the term “paramedics,” developed human growth hormone, and was involved in the early development of the profession of Nurse Practitioner. It is academically affiliated with the David Geffen School of Medicine at UCLA and works in partnership with the Harbor-UCLA Medical Center.
Grob spoke with Lucid News to reflect on The Lundquist Institute study and the history of research into the use of psychedelic substances for treating the mental health needs of people with terminal illness.
A $1.75 anonymous donation is significant. Who donated the funds for this study?
Dr. Charles S. Grob: I am sworn to secrecy. My lips are sealed. I haven’t even told my wife or daughter.
What makes The Lundquist Institute research unique in the study of psychedelic substances?
What makes this study different from preceding studies is that it has broadened the patient population, it will take place in palliative care settings, and it will train practitioners. There has been a strong level of interest in investigating the palliative treatment model at national and international palliative care conferences. We will be training different palliative care practitioners including doctors, nurses, chaplins, social workers and psychologists.
What also makes this research different is that in the pioneering investigations with psychedelics in the 1960’s and in the modern era, we looked at individuals with advanced cancer. In this study, we are opening it up to people with many additional medical illnesses that might be fatal and who are already enrolled in palliative programs.
When will the study start and how will it be structured?
I think it will start early next spring. We need to still finalize our protocols and submit them to regulatory agencies and go through an Institutional Review Board (IRB) presentation next spring or next summer. It will be a double-bind placebo controlled study and we have budgeted for 60 subjects, but we have been advised to estimate about 80 subjects.
We are not advocating that people use psychedelics in the dying process. The study subjects must have an estimated life expectancy of six months and a palliative care diagnosis for an illness that could lead to a potentially fatal outcome. The study will take place at four to five different sites around the U.S. using the same methodology, the same entry criteria, and the same outcome measures. I would imagine five to six researchers at each site. I can’t confirm the sites at this time.
Another potential complication is this strange world we live in with Covid. How are we going to administer psychedelic treatment in the age of Covid-19? This is going to be challenging because we will be in relatively close proximity to study subjects for many hours. We could be in a small space. Society needs to be in a much healthier place to do this kind of study and go through all the hurdles. I’m sure we will work this out and other groups working with psychedelics will work this out.
Why is this study needed now?
The study of psychedelic substances has gone from a small field to expanding rapidly into something that at times feels over the top. I am concerned that proper attention to establishing safety parameters – and the importance of that in this context – may not be a priority for some investigators. It’s good to see enthusiasm for this research, but people implementing these studies need to prioritize the need for safety and established ethical standards. I have written a paper with other researchers on the need for strong ethical standards and safety parameters which we will publish this year.
Is this study historically significant?
Yes. This is the first study of this sort since the 1960s or early 1970s. In the 1960’s, this was one of the most promising areas for psychedelic-assisted treatment. In the early 1960’s, Dr. Eric Kast, a pain specialist at the Chicago Medical School, conducted research administering LSD to hospital patients in chronic pain and recorded positive effects in pain reduction, improved mood, outlook and quality of life with less fear of death. This research was followed up by Walter Pahnke, Stanislav Grof, and Bill Richards who did work in the late 1960’s and early 1970s finding dramatic effects with the improvement of anxiety and the reduction of pain.
They found that the strongest predictor of positive therapeutic outcome was, during the course of the session, the patient having a powerful psychospiritual epiphany. Humphry Osmond, in the late 1950’s, also found that this predicted the best outcomes while studying the use of psychedelics to treat people with alcohol dependency.
Why did this research stop moving forward after the initial studies in the 1960’s and 1970’s?
The psychedelic research in the 60s and 70s was not halted due lack of positive outcomes or the safety of the research. It was stopped for cultural and political reasons. It got conflated with the culture wars of the 60’s and was identified with a politically active counterculture. In the 60’s, the divisiveness became a cultural divide and psychedelics became a sacrament for the counterculture. You were on one side or the other side.
Some leaders like Timothy Leary, who was a brilliant researcher, also had a penchant for being very provocative and the compounds were eventually considered too hot to handle. There was no approved research in the U.S. from the early 1970s to the early 1990s, when our team conducted the first clinical study with MDMA. Our Phase 1 study of MDMA was also around the same time as Rick Strassman’s investigation of DMT and Deborah Mash’s study of ibogaine. These three studies were the first approved investigations of psychedelics since the late 1960s and early 1970s.
What has changed culturally that has allowed this research to continue now?
The Archives of General Psychiatry, which published our pilot study in 2011, accepts a miniscule number of papers. Why did they accept ours? They recognized that psychiatry needs new and novel and more effective treatment models and after decades of quiescence, the world we live in has changed and investigating psychedelics has once again become accepted and respected. Our values have changed and we have a more mature manner in which this research is recognized. In the 60’s it was brand new and it took the culture by surprise.
By the late 1990s and the early 2000’s, we had weathered the tempest and were in a more open and receptive phase. There was recognition that conventional treatments in psychiatry are sometimes helpful, but sometimes lacking in efficacy. As healers and scientists, it is important to objectively examine new and novel treatments for people who do not get substantial relief from conventional treatments.
What researchers most influenced your work with psychedelic substances?
We were the first to work with an advanced cancer population and we basically took Stanislav Grof’s work and investigations from that era and adapted it, modernizing the protocol and changing some of the criteria. But the inspiration came from the pioneering research of Grof and Walter Pahnke, Gary Fisher, Bill Richards and others.
Those who came before these investigators were the true experts and authorities on psychedelic plants. The indigenous people throughout the world knew the plant life in their geographic areas and used these plants for healing and divination and spiritual purposes. I would like to credit not only the prior generation of investigators, but the indigenous people who have been historically mistreated. They kept the tradition of plant hallucinogens alive and concealed them from the Spanish and Portugese invaders.
What has most influenced your thinking about the dying process?
My views began forming early. Before I pursued my training in psychiatry and internal medicine, I grew up in a household where my father was a prominent internist. I grew up in that medical world and observed with patients and family members that the dying process is often associated with very severe psychological pain, isolation, alienation and existential distress.
I encountered Grof’s work in the early 1970s and his case reports of working with individuals not just undergoing physical suffering, but also psychological and psychospiritual pain and anguish. I would look at patients on medical floors and say, “there has got to be a better way.”
Aldous Huxley also had a beautiful image in his novel Island of how these compounds might help the passage from life to death. Grof’s work was very encouraging. I took his message to heart as I got my credentials and training and waited for a time to again do feasible human research with compounds that had been taboo for a long time.
What role do you see psychedelics playing in the future of palliative care?
We can see how they could endow palliatieve practitioners with additional tools. We developed our study with Dr. Ira Byock, a former director of palliative medicine at Dartmouth-Hitchcock Medical Center. He is a palliative care practitioner who really made a significant contribution to the evolution of Tony’s [Bossis] and my thinking on that issue. He helped us to embark on this study.
What else should we know about this study?
I’ve worked for 27 years with The Lundquist Institute and the Harbor-UCLA Medical Center. They have always been very collegial and supported research ideas that in some quarters were considered taboo. I explained our rationale and safety parameters and they heard me out. They knew I could be trusted to conduct the early MDMA and psilocybin research and take the data back to UCLA and Lundquist.
Although we have received a very generous grant for this study, it’s only half of what we think we will need in the bank to get this research off the ground. If a research program already has funding, it is easier for other funders to make generous donations. That is what we hope will happen here.
TORONTO — For Thomas Hartle, every day is a challenge because of his anxiety.
The 52-year-old from Saskatoon has terminal cancer and the thought of the future triggers his anxiety on a daily basis.
“It gives you a rapid heart rate. It makes you feel terrible,” he shared with CTV News’ medical correspondent Avis Favaro.
Hartle has tried everything from anti-anxiety medication to meditation to treat the symptoms of his anxiety, but he’s hoping for a more long-lasting solution to ease his distress.
That is why he’s one of a handful of terminally ill Canadians who are appealing to the federal health minister for a special exemption on compassionate grounds that would allow them to use an illegal drug found in “magic mushrooms.”
The drug is called psilocybin and is a naturally occurring psychedelic compound produced by several species of mushrooms.
Growing research on the psychedelic appears to show that it has the potential to provide long-term relief for anxiety and depression, particularly among terminally ill patients suffering from “end of life” distress.
Scientists around the world have found the drug shows promise in being able to rewire the brain and boost mood in patients, with one study showing that up to 80 per cent of palliative patients reported reductions in depression and anxiety, and improved attitudes towards death.
In one U.S. study published in the Journal of Psychopharmacology in January, patients with cancer-related psychiatric distress continued to experience reductions in anxiety, depression, hopelessness, demoralization, and death anxiety more than four years after a single dose of psilocybin in combination with psychotherapy.
Researchers at the U.S. Center for Psychedelic and Consciousness at Johns Hopkins University in Baltimore are currently conducting Phase 3 clinical trials with the aim of having psilocybin approved for market as a prescription medication.
Roland Griffiths, the centre’s director, told CTV News earlier this year they initially faced a lot of skepticism about the safety of the drug. Since then, they have published multiple studies on the benefits of using one dose of psilocybin in a treatment that runs approximately six hours and has few side effects.
“Psilocybin produces conditions under which people report having a sense of increased efficacy, a change of world view, a sense of change of self, and that they’re able to re-engage in the world in very positive ways,” Griffiths said during an interview with CTV News in February.
That inner change is one of the reasons why Hartle is appealing to Health Minister Patty Hajdu to grant him legal access to psilocybin for compassionate reasons.
“Most people come out of this experience with a more spiritual connection to whatever it is they believe in. For me, that is an appealing thing,” he said. “What I am looking for is something that helps me deal with problems and anxieties that I just don’t have another mechanism of dealing with.”
In order to legally possess and use psilocybin, Hartle has to apply for a Section 56 exemption of the Controlled Drugs and Substances Act and be approved by Hajdu.
Hartle isn’t the only one opting for this route, either.
In January 2017, Bruce Tobin, a psychotherapist and professor at the University of Victoria, applied to the minister of health for a special exemption that would enable him to legally possess and use psilocybin to treat patients experiencing end-of-life distress.
After three years, he said his application was rejected in early March on “the basis that there is insufficient evidence to demonstrate the medical need for psilocybin.”
Now, Tobin has pivoted his focus to helping individual patients apply directly to Hajdu for special exemptions with the assistance of his group TheraPsil.
TheraPsil is a non-profit coalition of health-care professionals, patients, and advocates who are working to gain legal access to psilocybin on compassionate grounds as well as provide public education, training for health professionals, and expanding research on the drug.
“Canadians now have the right to die and this was legally recognized in the medical assistance in dying legislation that came in a few years ago,” Tobin told CTV News during an interview from his home in Saanich, B.C.
“If Canadians have the right to die acknowledged, surely they must have the right to try. The right to try a novel medicine. The right to try to have a better life before they finally do pass away.”
While there is enthusiasm for the use of psilocybin as a treatment for anxiety and depression, there are some scientists who say there isn’t enough proof yet to demonstrate the drug’s efficacy and safety for widespread use.
Dr. Martin Chasen, a palliative care physician and the medical director for palliative care at William Osler Health System in Ontario, noted that in studies on psilocybin, psychotherapy sessions are mandatory as part of the treatment, patients are carefully selected, and the drug is administered in a controlled environment.
“A multisite study in a larger and more diverse patient population should be conducted to establish the generality and safety of psilocybin treatment of psychological distress associated with life-threatening cancer,” he said.
Although there may be doubts about psilocybin’s use in medicine, Toronto lawyer Paul Lewin said medical cannabis was also once off-limits before the pressure grew from those who felt they had no other option.
“There’s a lot of peer-reviewed, rock solid research supporting it,” he told CTV News. “Hopefully, it is not necessary to have endless litigation as it was with cannabis.”
That’s what Hartle hopes as well, as he pushes to have his case pave the way for others behind him.
“Not everybody has terminal cancer, but there are a lot of people who also suffer from anxiety and depression out there,” he said. “If my going through the discomfort of having to apply for this and ask for permission to use this will benefit somebody else whose anxiety is stopping them from doing this… then that’s a purpose.
Everyone wants to have something that they can leave behind.”
Psychedelic Drugs Can Improve Quality Of Life – And Death – For Older Adults
Abbie Rosner – Contributor
Vices – I cover how older adults are discovering and re-discovering cannabis.
Even before COVID-19 set off a global tsunami of anxiety and depression, psychedelic drugs were already showing exciting promise for treating these and other intractable mental health conditions.
Compass Pathway’s recent raise of $80M to expand research into the clinical uses of psilocybin only affirms that no coronavirus is going to dampen efforts to make these treatments legal and widely accessible. If anything, the need for an effective answer to COVID-era angst makes this work even more urgent.
Especially for Baby Boomers and their elders, developments in the psychedelic space are worthwhile following, particularly because of their potential to radically improve quality of life, up to its inevitable end.
Older Americans suffer disproportionately from chronic pain and its attendant ailments, anxiety, depression and insomnia. In the search for relief, they consume more pharmaceutical drugs than perhaps any comparable cohort on this planet.
Psychedelic therapies to treat mental health conditions offer a radical departure from current pharmaceutical models that wed individuals in a lifelong bond of drug-taking. Instead, the psychedelic therapy modalities currently under investigation combine a limited number of treatment sessions with a psychedelic substance, sandwiched between intensive pre- and post-treatment therapy sessions. The ideal, and realistic, outcome from this course of treatment is not mere symptom control but durable remission.
High Stakes: Will The Legalization Of Psychedelics Mimic That Of Cannabis? Will It Learn From Its Mistakes?
DoubleBlind Mag – March 10, 2020
By Double Blind‘s Madison Margolin, provided exclusively to Benzinga Cannabis.
The cannabis industry has drifted from its grassroots values. Will the psychedelic field learn from its mistakes?
I’m in the back corner of a Hollywood cafe and I just took a hit off my vape pen. For focus, mainly, and to get some creativity flowing. No one seemed to notice or care, plus the vapor smells more like rose than like weed. The pen itself is pink, now sitting in the front pocket of my purse with my earbuds, chapstick, car keys, and a small jar of cannabis salve for my tendinitis.
At home, I have a ziplock baggie of psilocybin mushrooms hidden in my bedroom. They’re tucked away with a square of tin foil wrapped around some MDMA powder. The baggie, the foil, the hiding spot—it’s the definition of a “drug stash.” The last time I treated cannabis this way was my freshman year of college nearly a decade ago.
Things have changed since then, at least here in California. My designer weed feels like an accessory to my makeup bag, and I can’t remember the last time someone gave me bud in a ziplock. I know it’s only a matter of time before psychedelics go the same way. But do we want them to?
Granted, microdosing psychedelics is on its way to becoming almost as socially acceptable as vaping cannabis before work. As of a 2013 National Survey on Drug Use and Health, nearly 7% of the American population had taken MDMA, while on any given weekend, dozens of ayahuasca ceremonies are happening in lofts, yoga studios, and private homes all over Brooklyn, Los Angeles, the Bay Area, and beyond.
Psychedelics are fast re-entering the mainstream, with prudent visionaries, scientists, and academics like Rick Doblin, founder of the Multidisciplinary Association of Psychedelic Studies, Michael Pollan, author of How to Change Your Mind, and Johns Hopkins’ researcher Roland Griffiths, among others, leading the way.
Though disproven as a gateway drug, cannabis indeed is a gateway plant, introducing consumers to a plant-based approach to wellness. Having experienced the power of cannabis therapy, those who may otherwise have feared psychedelic “drugs” are seeing their merit.
The approach to cannabis legalization has been threefold. The most obvious route has been local, with state measures to decriminalize or legalize cannabis for medical or recreational purposes. Key players in state markets like California’s, luring the brightest minds in marketing, have rebranded cannabis as a wellness and lifestyle product. Once embraced only by hippies, cannabis has been sterilized enough to lure even the most conservative squares (like John Boehner) into the industry. Congress is catching on, too, now considering a record number of bills to deschedule or otherwise promote cannabis law reform. The federal approach comprises the second route to reform.
Meanwhile, the third prong is through FDA rescheduling. Currently, Sue Sisley, president and principal investigator at the Scottsdale Research Institute, has partnered with MAPS to study cannabis flower as a treatment for veterans with PTSD. When the research is complete, the idea is for cannabis, in its organic form, to become an affordable, prescription medication.
“One of the things that the cannabis movement has done right is having operated in multiple levels of government,” says Noah Potter, author of The Psychedelic Law Blog and an attorney with cannabis firm Hoban Law Group. “There’s no central organizing on cannabis, but it has happened organically as people have stepped up in different capacities as journalists, as physicians, and as entrepreneurs, [while] for better and for worse, there’s a diversity of messaging on cannabis.”
Similar to organizations like the National Organization for the Reform of Marijuana Laws or the Drug Policy Alliance, MAPS, a nonprofit which has sponsored much of the recent, pioneering psychedelic research, has strong political leanings.
Yet MAPS and other research nonprofits are not alone in seeking to make psychedelics legal, as medications. There’s been concern among some key players in the psychedelic community that COMPASS Pathways—a for-profit company whose research has recently been put on the fast-track by the FDA to develop psilocybin therapy for depression—is an indication that people looking to profit from psychedelics, rather than ensure their accessibility, are getting into the space. The company is backed by major venture capitalists including Peter Thiel and Michael Novogratz.
We’re now seeing at least a two-pronged approach to psychedelics, mirroring cannabis. The first is government-approved research on MDMA for PTSD and psilocybin for anxiety, addiction, and other conditions. The second is state- and city-level initiatives in places like Denver and Oregon to decriminalize or legalize psilocybin. According to Oakland’s Decriminalize Nature campaign, more than 55 cities now want to replicate the city’s initiative, which passed in June, to decriminalize all naturally-occurring psychedelics.
But as Potter mentioned, the “diversity of messaging” has its drawbacks, too: Without a central tenant to either the cannabis or psychedelic movement, there’s no way to ensure these industries grow to be accessible or equitable.
How is it that in the cannabis industry, for instance, thousands of Drug War victims (mainly people of color) remain incarcerated for minor cannabis violations, while white men (those like Boehner) make headway in yet another increasingly corporate American industry?
“You combine cannabis with capitalism, in which cannabis is now just a consumer product, and it’s now just all about the money,” Potter says.
Consequently, we’re now in a place where even black market farmers and gray market dispensary owners, who for decades lived under the looming threat of having their livelihoods taken from them, are bemoaning legalization amid burdensome regulations and an inability to compete with Big Marijuana. And whereas women once comprised 36% of executives in the cannabis industry, the mainstreaming of pot has had the side effect of reducing that statistic by about 9%, according to a 2017 survey by Marijuana Business Daily. With a number of industry execs having never even gotten high themselves, it’s hard not to wonder how the cannabis industry digressed so far from the morals of its original, grassroots movement.
And that’s just the question we should be asking about the coming psychedelic industry: How can the commercial market uphold the values of community and compassion so often reinforced when a person is under the influence of these entheogenic plants?
While, admittedly, there are far fewer prisoners of the War on Psychedelics than the War on Weed, equity in the case of psychedelics means not only including marginalized groups in the nascent industry, but ensuring psychedelic medicine as a right, rather than a privilege. Also, says Potter, to go about psychedelic legalization solely for the purpose of providing medicine feeds into the prohibitionist paradigm that these substances may still be unsafe outside that paradigm; it neglects their merit in recreational or spiritual purposes, the line between both often being hazy.
There remains a need, within the movement, to uphold the right to cognitive liberty, the pursuit of happiness, and the innate yearning for spiritual connection—all alongside the need for better medicine. At the same time, we need to ensure that the movement and industry give due respect to the indigenous cultures that have been using these substances, safely and wisely, for generations. “You now have potential exploitation of these substances for-profit and first-world psychedelic tourism,” says Potter.
Ultimately, psychedelic legalization would be preferable to decriminalization, Potter argues, because it would allow psychedelics to be regulated and make a larger dent in the Drug War. But, in order for psychedelics to actually become integrated into society, the medical-spiritual-commercial divide will have to shift, too. If done properly, says Potter, “that will have profound implications for everything we do.”
The growing push for medical use of psilocybin in Canada
CTV News – February 15, 2020
TORONTO — Growing evidence about the powers of psilocybin, a naturally occurring psychedelic compound produced by several species of mushrooms, being used to treat anxiety and depression has inspired advocates to file a federal court challenge next month to allow its use to treat terminally ill patients.
Psychotherapist and professor at the University of Victoria Bruce Tobin has been on the forefront of those advocating to end the prohibition of the drug – highlighting its potential for cancer patients who often suffer from what is described by doctors as “end of life distress.”
End of life distress is a “nasty combination of anxiety, depression hopelessness and demoralization that often accompanies the diagnosis of a terminal illness such as cancer,” Tobin said in an interview with CTV News’ medical correspondent Avis Favaro. “My desire is to get the treatment to patients who are in need of it right now.”
Psilocybin found in what is colloquially known as “magic mushrooms” is illegal in Canada, but Tobin said he has witnessed patients undergoing psychotherapy feel calmer and less stressed by using the compound.
“We can see the results in many cases very quickly, as quickly as the next day,” he said.
Tobin says he has been waiting three years for Health Canada to respond to multiple applications for psilocybin’s compassionate use in terminally ill patients.
“My attitude now is treatment delayed is treatment denied,” Tobin said, explaining that he will continue to push for psilocybin to be exempted from the Controlled Drugs and Substances Act.
Three thousand patients per year in Canada are suffering from “end of life distress” and fit the criteria for so-called psilocybin-assisted psychotherapy, Tobin said.
His campaign is supported by a group he formed, entitled “TheraPsil: Therapeutic Psilocybin for Canadians,” which lists the scientific, legal and moral reasons the group believes the compound should be made legal for “end of life distress” cases.
Research into the medicinal uses of psilocybin has been growing exponentially.
A U.S. study published in the Journal of Psychopharmacology in January showed that cancer patients who were given the compound reported reductions in anxiety, depression, hopelessness, demoralization and death-related anxiety more than four years after receiving their doses in combination with psychotherapy.
A second study from the U.K. in the Journal of Psychopharmacology suggested that when given to patients with treatment-resistant depression, psilocybin affected “functional connectivity” changes in the brain which was evident in scans. The study suggested that “psilocybin therapy improves how the brain works and revives emotional responsiveness.”
The field of psychedelic research is “very exciting” according to professor Roland Griffiths, director of the Center for Psychedelic and Consciousness at Johns Hopkins University in Baltimore.
Griffiths’ centre was the first to obtain regulatory approval in the U.S. to restart research into psychedelics using healthy volunteers. Previous research into psychedelics met an abrupt end during the war on drugs in the 1970s.
“When we initiated this research there was a fair bit of skepticism on the part of many, my colleagues and certainly regulators, about whether or not this work is safe,” Griffiths said in an interview with CTV News.
Now his research group is publishing an array of studies on the benefits of using one dose of psilocybin in a treatment that runs approximately six hours and has few side effects and displays benefits to patients’ perceptions.
“Psilocybin produces conditions under which people report having a sense of increased efficacy, a change of world view, a sense of change of self, and that they’re able to reengage in the world in very positive ways,” Griffiths said.
Griffiths said that as patients reflect back on those experiences with psilocybin, they “often have this sense of a profound coming to an understanding of a deeper level of who they are.”
With many psychiatric disorders proving difficult to treat, Griffiths said the team at Johns Hopkins is expanding its testing of psilocybin and other psychedelics, such as LSD, for conditions including obsessive compulsive disorder, post-traumatic stress disorder, opioid use disorder, alcoholism and anorexia nervosa.
Other research is examining the benefits of microdosing, which uses small doses of psilocybin to treat anxiety and depression. A survey of people self-managing mental and substance use disorders by microdosing found 44 per cent of them perceived their mental health was “much better” as a result.
Some Canadians are not waiting for the studies.
Michael Ljubsa of Edmonton, Alta., struggled with depression when he left high school and began university, and said he was unable to find relief with the standard therapies or medications available to him.
“I just became like a zombie basically,” he said in an interview with CTV News. “It became just difficult to function.”
Ljubsa experimented with psilocybin in Jamaica, where it is legal, to try and help – not something doctors recommend – and described a change in self-perception he found “liberating” and boosted his mental wellbeing. He is now an advocate of further psilocybin research.
“Any sort of work that is being done to bring this medicine to people as fast as possible is the work that needs to be done,” Ljubsa said.
At least two centres in Canada are pursuing studies of psilocybin. The University of Toronto Mississauga has launched a Centre for Psychedelic Studies and will host the world’s first clinical trials on microdosing psilocybin. Other related research is planned at the University of British Columbia’s School of Population and Public Health.
“I think we are entering a new era in the treatment of mental health conditions,” Griffiths said.
“Psilocybin and these compounds have mechanisms unlike anything we have seen within our normal treatment options within psychiatry,” he continued. “The potential…to have efficacy across a range of conditions is absolutely remarkable. We just don’t understand the mechanisms of them yet.”
Cybin Partners With Toronto Centre For Psychedelic Science For Psilocybin Research Project
by Natan Ponieman – February 13, 2020
Cybin Corp., a Canadian life sciences company focused on psychedelics and mushroom-psilocybin research, announced a new partnership with the Toronto Centre for Psychedelic Science.
With this partnership, the centers’ co-founders, Rotem Petranker and Thomas Anderson will be appointed exclusive clinical advisors to Cybin.
“We feel many of the positive results that people have experienced with psychedelics require further scientific study with transparently-disclosed protocols and proper research study architecture to achieve repeatable results,” Paul Glavine, CEO of Cybin Corp. told Benzinga. “Rotem and Thomas’ commitment to open science echoes our philosophy. Together we expect to build a solid foundation and future for this industry, grounded in research and the scientific method.”
The consumption of psychedelic drugs such as psilocybin is correlated with “persisting reductions” in the use of cannabis, opioids and stimulants, noted new research published this week in the journal Frontiers in Psychiatry.
Researchers from the John Hopkins School of Psychiatry and Behavioral Sciences and the Department of Neuroscience, The Ohio State College of Social Work and the Erowid Center contributed to the study.
“Observational data and preliminary studies suggest serotonin 2A agonist psychedelics may hold potential in treating a variety of substance use disorders (SUDs), including opioid use disorder (OUD),” researchers wrote.
The study recruited 444 adults via advertisements online who claimed to have overcome addictions to alcohol and/or drugs through the use of psychedelics. Each participant completed an anonymous survey that assessed a variety of factors, including problematic substance use.
Researchers discovered that the majority of subjects in the study self-reported using psilocybin (a compound in so-called “magic mushrooms”) or LSD to provoke a psychedelic experience.
On average, participants reported about 4.5 years of problematic substance use. Approximately 79 per cent of study participants met the retrospective criteria listed in the DSM-V (Diagnostic and Statistical Manual of Mental Disorders) for severe substance abuse disorder prior to consuming psychedelics, and 96 per cent met the criteria for substance use disorder.
After their “psychedelic experience,” researchers say that only 27 per cent met the criteria for substance abuse disorder.
Participants who consumed higher doses of psychedelic substances, and reported more “mysticism,” epiphanies or insight as a result of the consumption, had a tendency to report a more substantial reduction in the consumption of other drugs.
The study’s authors emphasize that more research is needed to evaluate the connection between psychedelics and addiction, but that the results offer a promising direction for further study.
“While these cross-sectional and self-report methods cannot determine whether psychedelics caused changes in drug use, results suggest the potential that psychedelics cause reductions in problematic substance use, and support additional clinical research on psychedelic-assisted treatment for SUD,” the authors noted.
“The results of the study are clinically reassuring and support further development of psilocybin as a treatment for patients with mental health problems that haven’t improved with conventional therapy, such as treatment-resistant depression,” said James Rucker, the study’s lead researcher, according to the Independent.
Phase one of the study was meant to examine if psilocybin — the psychoactive component of mushrooms — is safe for consumption while phase two, currently underway, examines the therapeutic potential of the drug.
As part of phase one, 89 subjects were given 10 mg of psilocybin, 25 mg of psilocybin or a placebo during a six-hour session with a therapist. There were 25 dosing sessions and a follow-up period of six weeks.
While researchers found expected adverse effects related to mood and sensory perception, cognitive and emotional functioning were not negatively impacted.
“This study is part of our overall clinical development programme in treatment-resistant depression,” said Ekaterina Malievskaia, co-founder of Compass Pathways, the company behind the study. Phase two trials are taking place in Europe and North America using 216 patients to test psilocybin’s ability to treat depression.
With the legalization and decriminalization of cannabis making news and opening up new avenues of research around the world, the paradigm has already shifted on psilocybin mushrooms.
Denver became the first city to decriminalize the drug earlier this year and a handful of cities have begun to follow suit. California and Oregon organizers are hoping to get a legalization question prepared in time to make the 2020 ballot for a state vote.
Unlike some drugs that treat anxiety and other mental conditions, psilocybin is not prone to dependence. But given its hallucinogenic effect, lawmakers may be reticent to allow distribution of the psychedelic drug without more restrictions.
Vogue speaks to psychiatry experts about the latest research into psilocybin, the active agent in ‘magic’ mushrooms, which is proving to be an incredibly effective mental health treatment.
Ellen Burney – 28 January, 2020
Could the hallucinogenic love drug of the 1960s soon be a regular feature in mainstream medicine? The prospect is not so far out. After decades of antidepressants failing to deliver ‘happiness in a pill’, neuroscientists and psychiatrists are now rooting for a dose of psilocybin – the active agent in ‘magic’ mushrooms – to treat depression, anxiety, addiction and more.
Psilocybin is the latest in a boomlet of party drugs finding new status on the world stage of mental health medicine. Esketamine (derived from ketamine) was licensed for supervised use in treatment-resistant depression by The US Food and Drug Administration (FDA) in March 2019, and the European Commission in December 2019, but with this drug critics warn of a potential for abuse. Studies into psilocybin, however, suggest its therapeutic benefits to be fast working, non-addictive and side effect-free.
The World Health Organization (WHO) estimates that more than 264 million people globally suffer from depression, and about one-third do not respond to antidepressants; while close to one billion people suffer from a mental illness or substance abuse disorder. “There has been a dearth of major breakthroughs in mental healthcare for several decades now,” says Dr Robin Carhart-Harris, head of the Centre for Psychedelic Research at Imperial College, London, which opened in April 2019 – the first of its kind.
“Despite record breaking increases in prescription rates of psychiatric medications, this is not impacting on rates of mental illness – indeed these are going up instead of down – so clearly something is very wrong,” Carhart-Harris continues. “My strong hope is that the development of psychedelic therapy will have a revolutionary impact on mental health care, bringing the ‘care’ component back and transforming societies and systems as a result.”
The psychedelic therapy research
Back in 1962, Dr Timothy Leary started the Harvard Psilocybin Project, but before long there was a backlash against LSD and in 1971, the United Nations made psilocybin mushrooms a Schedule I drug – like heroin. Signalling a seismic shift in gear since that shutdown, the FDA finally granted ‘Breakthrough Therapy’ status to psilocybin in 2018, meaning an accelerated review and development of the drug due to its potential to treat a serious condition.
“To date, the classic psychedelics like psilocybin and LSD have been most extensively studied for mood issues such as depression, existential distress related to serious illness and substance use problems,” explains Dr Albert Garcia-Romeu, an instructor at the Center for Psychedelic and Consciousness Research, which opened in September 2019 at Johns Hopkins University of Medicine in Baltimore.
“In each of these areas we’ve seen very promising early results in small trials that are currently being expanded on in larger studies at Johns Hopkins and around the world,” Garcia-Romeu continues. A research project at the University of San Francisco, California, is testing psilocybin for distress in patients with AIDS, and in addition to psilocybin, Johns Hopkins is also researching MDMA-assisted therapy for post-traumatic stress disorder and anorexia.
What does a day in psychedelic therapy look like?
“This treatment is a new paradigm of psychiatric medication,” says Dr Matthew Johnson, associate director at the US research centre. “The medication prompts an experience and therapeutic process from which the person can learn. In many ways it is more like medication-induced deep psychotherapy.” Or the medical equivalent of hallucinogenic healing under chaperone of an ancient spiritual shaman.
“High-dose psilocybin has pronounced psychoactive and mood-altering effects for most people within one hour of taking the drug, usually subsiding within six to eight hours of administration,” explains Garcia-Romeu. “These effects are largely mediated by activity at the serotonin 2A receptors, and likely other downstream mechanisms that we are just beginning to tease apart.”
In a day-long clinical session, supervised by two therapists, trial patients are given a dose of 20 to 30 milligrams of pure psilocybin. “This corresponds to, on average, about four to five grams of dried psilocybe cubensis mushrooms, the most common type in the illicit market,” Johnson tells Vogue. “They wear eye shades to focus attention inward, and headphones through which mostly classical music is played. They are told to ‘trust, let go, be open’ and not to resist the experience.” There’s no therapy during the session, but patients can discuss the experience afterwards and will have a follow-up psychotherapy session the next day.
“This is not ‘take two and call me in the morning,’” warns Johnson, stating that psilocybin will never be available over the counter. “[Treatment] would resemble our current research trials, which are much like outpatient surgery, but with even more preparation and follow-up care.” The treatment – which he expects to be FDA-approved for depression in a couple of years – will always be delivered alongside psychotherapy. So, around 12 one-hour sessions of talking therapy with two doses of psilocybin.
The psychedelic therapy side effects:
1. The anti-zombie effect
Rather than the notorious ‘zombie’ side effect of selective serotonin reuptake inhibitors (SSRIs, such as Prozac), therapy sessions incorporating psilocybin appear to expand rather than numb emotions. “People typically report feeling more connected as opposed to disconnected from their life,” Johnson notes.
Carhart-Harris agrees. “Most conventional drugs come with a bunch of side effects and if they work, they often do so through muting a person’s emotional range. Psychedelic therapy brings multiple advantages: it can work after just one or two sessions (unlike psychotherapy or standard drugs, which can take weeks or months to work) with minimal toxicity and people can remain well long after the drug has left their bodies, sometimes entirely transforming their sense of well-being and life satisfaction.”
2. The sense-of-self effect
“The on-going research on the efficacy and safety of psychedelic medicine is very promising indeed,” notes Dr Michalis Kyratsous, consultant psychiatrist at South London and Maudsley NHS Foundation Trust.
“Subjects using psilocybin have reported a profound alteration to their ordinary sense of self, known as self-dissolution,” “And this effect can be potentially used to address specific set of symptoms, such as excessive self-focus in depression.”
3. The enlightening effect
There also appears to be an enlightening effect. “It’s a deeply held spiritual experience that seems to connect people to themselves, to others around them, to the universe,” says Dr Alan K Davis, assistant professor at the US research centre, who also guides the psychedelic therapy sessions. “That type of experience also can include things like psychological insight, where someone is gaining new information or awareness about themselves, the world around them, their relationships or past experiences.”
“A reminder this is not a daily medication,” Davis emphasises. “It’s a medication that people take twice with therapy. The fact that we can see these long-term results, compared to medications that they will have to take every day for the rest of their lives, is pretty remarkable.”
City of Santa Cruz Decriminalizes ‘Magic Mushrooms’ and Other Psychedelics
January 30, 2020, By CNN Wire
The city of Santa Cruz, California, has become the latest city to decriminalize “magic mushrooms” and other natural psychedelics, including ayahuasca and peyote.
The Santa Cruz City Council voted unanimously to approve a resolution that makes investigating and arresting people 21 and older for using or possessing psychoactive plants and fungi among the lowest priorities for law enforcement.
Tuesday’s resolution doesn’t necessarily make it legal to use or possess natural psychedelics, but it does mean that the city won’t be using resources to investigate or arrest people for doing so. People could still face penalties for the sale or cultivation of those substances.
The resolutions or ordinances passed by Santa Cruz, Oakland and Denver don’t apply to drugs such as LSD or MDMA, which are synthetic.
Other places are considering similar measures
Chicago is among other cities considering a resolution to decriminalize certain psychedelics, and efforts to enact similar measures are underway in some states.
In Oregon, a campaign called PSI 2020 is lobbying for a measure on the ballot that could make the use of psilocybin, the hallucinogenic compound found in psychedelic mushrooms, legal statewide.
If the measure passed, the Oregon Health Authority would oversee a program that would allow psilocybin to be administered in licensed therapeutic environments and supervised by trained professionals. People would not need a mental health diagnosis to receive therapy, according to the language in the measure.
“We think that this novel approach could help alleviate the mental health crisis here in Oregon by addressing epidemics like suicide, treatment-resistant depression and anxiety, PTSD, and addiction to drugs, alcohol, and nicotine,” PSI chief petitioners Tom and Sheri Eckert say on the campaign’s website.
“Additionally, the measure would open doors for new research and create access to services for those interested in personal development.”
A campaign for a similar measure on the ballot in California is also underway, after it failed to get enough signatures last year. That measure would decriminalize personal possession, use and cultivation of psilocybin statewide for people 18 and older.
Last year, Iowa Republican state representative Jeff Shipley introduced two bills in the legislature to decriminalize psilocybin used for medicinal purposes, and remove it from the list of schedule I controlled substances.
Research suggests psychedelics have health benefits
Natural psychedelics have long been popular for recreational use, though many have been banned at the federal level for decades.
The US Department of Justice classifies psilocybin as a Schedule I controlled substance, which means that federal policy states that it has no currently accepted medical use and a high potential for abuse.
But a growing body of medical research suggests that psilocybin can be used to treat conditions such as anxiety and depression, in cases where drugs currently on the market cannot. It has also been found to have a low potential for abuse, and no potential for physical dependence.
A 2017 study published in the journal Nature showed that 47% of patients experiencing treatment-resistant depression showed positive responses at five weeks after receiving a psilocybin treatments.
And in 2018, researchers from Johns Hopkins University called for removing psilocybin from the list of Schedule I substances.
Psychedelics: Can getting high improve your mental health?
By Sandee LaMotte, CNN – January 24, 2020
(CNN) Can the mind-blowing effects of psychedelics help heal our traumas?
“The Goop Lab,” Gwyneth Paltrow’s new Netflix mini-series, tackles the topic in their first episode by sending several Goop employees to Jamaica to ingest magic mushrooms under the careful guidance of psychotherapists.
One young woman, traumatized by her father’s suicide, declares she “went through years of therapy in about five hours.”
What does the scientific community say about the role of psychedelics on our psyche?
It’s an increasingly hopeful thumps up.
Despite the fact that psychedelics are illegal, the last decade has seen an explosion of research, with results so intriguing that governments are greenlighting studies around the world.
Watching ‘The Goop Lab’ could turn you into a member of the Goop troop
Scientists are busily exploring the role of hallucinogens on treatment-resistant depression, post traumatic stress disorder, cancer-related anxiety, addictions, and even anorexia.
But this is not the first time science became giddy over the potential benefits of psychedelics. That story began nearly a century ago.
The first trip on LSD
It was 1938 when Swiss chemist Albert Hoffman inadvertently synthesized lysergic acid diethylamide, or LSD, while trying to create a treatment for bleeding disorders. He shelved the compound for other research, then accidentally absorbed a small dose a few years later.
Johns Hopkins has launched the first center devoted exclusively to researching psychedelic drugs in the U.S.
Intrigued by the feeling of euphoria, Hoffman tried it again, later realizing he had given himself five times the effective dose.
“The faces of those around me appeared as grotesque, colored masks,” Hoffman wrote in a first person account. “I sometimes observed, in the manner of an independent, neutral observer, that I shouted half insanely or babbled incoherent words. Occasionally I felt as if I were out of my body.”
Hoffman was tripping.
The golden era
Word spread quickly through the scientific community and soon researchers around the world began analyzing, then experimenting with LSD, both on themselves and their patients.
Their methods may not be considered state-of-the-art science today, but that didn’t stop the research. Science began to tackle other age-old hallucinogens: an extract from Mexican “sacred mushrooms” called psilocybin, and a naturally occurring psychoactive found in the peyote cactus called mescaline.
Forget weed. Some Oregonians want to legalize psychedelic mushrooms
After all, these plant-based psychedelics have been in use by indigenous peoples and ancient cultures for hundreds, possibly thousands of years.
In the 1950s UK psychiatrist Dr. Humphry Osmond began giving LSD to treatment-resistent alcoholics: 40% to 45% of those who took LSD were still sober after a year. Other researchers duplicated his results.
Eager to label the effect of LSD on the mind, Osmond put together the Greek words psyche (mind) and deloun (show). The word psychedelic was born.
During the ’40s and early ’50s tens of thousands of patients took LSD and other psychotropics to study their effects on cancer anxiety, alcoholism, opioid use disorder, depression, and posttraumatic stress disorder or PTSD. Researchers began to see psychedelics as possible “new tools for shortening psychotherapy.”
Outside the control of a lab, people began touse psychedelics for their mind-bending effects, swearing the drugs improved creativity and made them happier long past the bliss of the high.
Celebrities helped spread the word: Gary Grant used LSD over 100 times in the late ’50s, according to the documentary film, “Becoming Cary Grant,” claiming it made him a better actor.
Grant was so taken with the drug that he decided to go public with his experience in the September 1, 1959, issue of Look magazine. Vanity Fair wrote about the article, entitled “The Curious Story Behind the New Cary Grant,” which was a glowing account of how LSD therapy had improved Grant’s life: “At last, I am close to happiness.”
Influential writer Aldous Huxley, best known for his 1932 novel “Brave New World,” took LSD during the last third of his life. In 1960 he told “The Paris Review”: “While one is under the drug one has penetrating insights into the people around one, and also into one’s own life. Many people get tremendous recalls of buried material. A process which may take six years of psychoanalysis happens in an hour — and considerably cheaper!”
The Leary impact
When Harvard psychologists Timothy Leary and Richard Alpert decided to open the Harvard Psilocybin Project in 1960, research on psychedelics was still in its golden era. That would soon change.
Leary and Alpert were fired in 1962 and their research shut down when Harvard discovered they had been giving LSD to their students. Alpert changed his name to Baba Ram Dass and became a best selling author and New Age guru. Leary began to speak out publicly, encouraging young people to take LSD recreationally. He quickly became the face of the drug counterculture movement with his signature message, “Turn on, tune in, drop out.”
“Drop out of school, because school education today is the worst narcotic drug of all,” Leary said. “Don’t politic, don’t vote, these are old men’s games.”
Unforgettable photos of psychedelia and debauchery from the golden age of LSD
No longer administered in the relative safety of a lab or psychiatrist’s office, horror stories of bad “acid” trips at colleges and concerts shared headlines with images of anti-Vietnam protests and unclothed Woodstock attendees.
In 1966, LSD was declared illegal in the United States and research projects were closed or forced underground.
In 1970, President Richard Nixon signed the Controlled Substances Act into law. It classified hallucinogenics as Schedule I drugs — the most restrictive category — reserved for substances with “no currently accepted medical use and a high potential for abuse.”
A long dry spell is broken
Twenty five years passed. Then in the mid-’90s, a few scientists in Germany, Switzerland and the US again began to explore the mental and physical impact of psilocybin, mescaline, and a new player in the space: N-dimethyltryptamine or DMT. It’s the active ingredient in an ancient sludge-like brew called ayahuasca, which is used by spiritual healers in the Amazon.
Small, with very few participants and no randomization or other controls, the research was similar to “safety and tolerability” studies designed to prove no harm.
Trying to study illegal substances created challenges for researchers, but many persevered. As the years passed, the US Food and Drug Administration and the US Drug Enforcement Administration began to say “yes” more often than “no.”
9 things everyone should know about the drug Molly
Studies on psilocybin, DMT, and mescaline were approved, as were studies of the synthetic drug MDMA, more commonly known as “Molly” or “Ecstasy.”
Research on LSD, which had the worst reputation in the public’s eye, lagged behind until 2008. That’s when the Multidisciplinary Association for Psychedelic Studies, or MAPS, received FDA approval to study LSD-assisted psychotherapy on end-of-life anxiety. MAPS called the approval “a transformative moment.”
The study found “positive trends” in the reduction of anxiety after two sessions of LSD administered under the guidance of a psychotherapist.
Fears of any permanent damage from psychedelics were eased by a large 2015 study of 130,000 American adults, comparing users to non-users. The study found no link between the use of LSD, psilocybin or mescaline and suicidal behavior or mental health problems.
However, studies show a minority of people do experience “bad trips,” fueling speculation that the chance of negative experiences maydiffer depending on the type of hallucinogenic, the dose, even the type of mental disorder. In addition, research shows people who have used anti-depressants for a long time fail to respond well to some psychedelics, leading to concern about their use in chronic anti-depressant users.
To avoid negative experiences, MAPS and other organizations say having trained therapists on hand to guide one through the experience is key, along with a supportive setting, appropriate expectations and proper dosage.
A research renaissance
Today there is a true renaissance of research on the role of psychedelics on mental health.
Active ingredient in ecstasy may help veterans with PTSD, study finds
“Gold-standard” double blind randomized trials have shown “rapid, marked, and enduring anti-anxiety and depression effects,” researchers say, in people with cancer-related and treatment-resistant depression after a single dose of psilocybin. Treatment with psilocybin has also improved obsessive compulsive disorder symptoms and alcohol dependence.
Dosage has become a focus of interest. “Micro-doses’ of shrooms and other psychedelics is a recent trend; users claim tiny, daily doses can improve mood and concentration without the commitment to a hours-long high. Research on micro-dosing is in the early stages.
MAPS is in the final phase of a gold-standard study administering MDMA [Ecstasy] to 300 people with severe PTSD from any cause. Results of the second phase showed 68% of the people no longer met the criteria for PTSD at a 12-month follow-up; before the study they had suffered from treatment-resistant PTSD for an average of 17.8 years.
The results are so positive that in January the FDA declared MDMA-assisted psychotherapy for PTSD a “Breakthrough Therapy.” MAPS hopes to turn the therapy into a FDA-approved prescription treatment by the end of 2021 to treat sexual assault, war, violent crime, and other traumas.
“We also sponsored completed studies of MDMA-assisted psychotherapy for autistic adults with social anxiety, and MDMA-assisted psychotherapy for anxiety related to life-threatening illnesses,” the group says.
Ayahuasca has been shown to significantly improve depression and appears to be helpful in treating alcohol, tobacco and cocaine addiction.
LSD has been shown to help anxiety, and studies find it provides a “blissful state” for the majority of users. Study participants report greater perceptiveness, insight, feelings of closeness to others, happiness, and openness. Some even say they experience long-term, positive restructuring of their moods and attitudes.
Psychedelic ayahuasca works against severe depression, study finds
But some studies have found unpleasant effects from LSD, both during the high and after. People with negative reactions can have difficulty concentrating, dizziness, lack of appetite, dry mouth, nausea and/or imbalance for up to 10 to 14 hours after taking LSD; headaches and exhaustion can last up to 72 hours.
In the end, it’s too early for science to provide psychedelics a full seal of approval. One of the caveats of this research is that the drugs are administered with psychological support. When that is removed, studies found the benefits were minimal, and in rare cases, may even worsen mental health symptoms.
“Psychedelics amplify painful memories … and emotions,” said MAPS trained psychiatrist Dr. Will Siu in the Goop episode. Taking these drugs in unsupported settings, he said, can “be incredibly destabilizing, and you can actually feel worse in the short term.”
Long term, it appears research into psychedelics is here to stay. Perhaps one day soon a trip to the therapist will include a trip into your mind, and hopefully, a quicker path to healing.
Interesting Mushroom information (not a Psilocybin mushroom but has healing benefits …)
Lion’s Mane: A Mushroom That Improves Your Memory and Mood?
Mushrooms provide a vast array of potential medicinal compounds. Many mushrooms are well-known for these properties, but the lion’s mane mushroom, in particular, has drawn the attention of researchers for its notable nerve-regenerative properties.
By – Paul Stamets – Founder, Fungi Perfecti; Advisor, Program of Integrative Medicine at the University of Arizona Medical School, Tucson – 08/08/2012 – Updated December 6, 2017
Mushrooms provide a vast array of potential medicinal compounds. Many mushrooms — such as portobello, oyster, reishi and maitake — are well-known for these properties, but the lion’s mane mushroom, in particular, has drawn the attention of researchers for its notable nerve-regenerative properties.
Lion’s mane mushrooms are not your classic looking cap-and-stem variety. These globular-shaped mushrooms sport cascading teeth-like spines rather than the more common gills. From these spines, white spores emerge. Lion’s mane mushrooms also have other common names: sheep’s head, bear’s head and the Japanese yamabushitake. I like the clever name “pom pom blanc” — a reference to their resemblance to the white pom-poms cheerleaders use. The Latin name for lion’s mane is Hericium erinaceus; both names mean “hedgehog.”*
Lion’s mane mushrooms are increasingly sold by gourmet food chains. This nutritious mushroom is roughly 20 percent protein, and one of the few that can taste like lobster or shrimp (Stamets, 2005). Lion’s mane is best when caramelized in olive oil, deglazed with saké wine, and then finished with butter to taste. Lion’s mane can be bitter if not cooked until crispy along the edges. It takes some practice to elicit their full flavor potential.
Lion’s mane mushrooms are increasingly studied for their neuroprotective effects. Two novel classes of Nerve Growth Factors (NGFs) — molecules stimulating the differentiation and re-myelination of neurons — have been discovered in this mushroom so far. These cyathane derivatives are termed “hericenones” and “erinacines.” The levels of these compounds can vary substantially between strains, based on the measurements our team has conducted.
About a dozen studies have been published on the neuroregenerative properties of lion’s mane mushrooms since 1991, when Dr. Kawagishi first identified NGFs in Japanese samples. Since his original discovery, in vitro and in vivo tests have confirmed that hericenones and erinacines stimulate nerve regeneration. In 2009, researchers at the Hokuto Corporation and the Isogo Central and Neurosurgical Hospital published a small clinical study. Giving lion’s mane to 30 Japanese patients with mild cognitive impairment resulted in significant benefits for as long as they consumed the mushrooms:
“The subjects of the Yamabushitake group took four 250 mg tablets containing 96 percent of Yamabushitake dry powder three times a day for 16 weeks. After termination of the intake, the subjects were observed for the next four weeks. At weeks eight, 12 and 16 of the trial, the Yamabushitake group showed significantly increased scores on the cognitive function scale compared with the placebo group. The Yamabushitake group’s scores increased with the duration of intake, but at week four after the termination of the 16 weeks intake, the scores decreased significantly.” (Mori, 2009)
Recently, mice were injected with neurotoxic peptides in an experiment to assess the effects of lion’s mane on the type of amyloid plaque formation seen in Alzheimer’s patients. The mice were then challenged in a standard “Y” maze, designed for testing memory. Mice fed with a normal diet were compared to those supplemented with lion’s mane mushrooms. As the peptide-induced plaque developed, the mice lost the ability to memorize the maze. When these memory-impaired mice were fed a diet containing 5 percent dried lion’s mane mushrooms for 23 days, the mice performed significantly better in the Y maze test. Interestingly, the mice regained another cognitive capacity, something comparable to curiosity, as measured by greater time spent exploring novel objects compared to familiar ones.
The reduction of beta amyloid plaques in the brains of mushroom-fed mice vs. the mice not fed any mushrooms was remarkable. The formation of amyloid plaques is what many researchers believe is a primary morphological biomarker associated with Alzheimer’s. Plaques linked to beta amyloid peptide inflame brain tissue, interfere with healthy neuron transmission, and are indicated in nerve degeneration.
The medical community is bracing for an increase of patients with Alzheimer’s and senile dementia as the baby boomer population ages. Mortality trends related to Alzheimer’s are outpacing death rates of many other diseases. This makes preventive and curative treatments of age-related cognitive diseases hot subjects of research. In the past 10 years, deaths from Alzheimer’s disease have surged roughly 66 percent, while deaths from other primary diseases have generally declined.
The influence of lion’s mane influence on neurological functions may also have other added benefits — making you feel good. In another small clinical study (n=30), post-menopausal women who consumed lion’s mane baked into cookies vs. those without showed less anxiety and depression yet improved in their ability to concentrate (Nagano et al., 2010).
Is this data conclusive thus far? No.
Is this data suggestive of positive outcomes? Absolutely.
In another small Japanese study with a randomized sample of 30 women, ingesting lion’s mane showed that “HE intake has the possibility to reduce depression and anxiety, and these results suggest a different mechanism from NGF-enhancing action of H. erinaceus.” (Nagano et al. 2010).
In light of the numerous diseases related to neurodegeneration, lion’s mane deserves more clinical attention. If lion’s mane enhances memory and is an antidepressant, can consuming this mushroom alter the course of Alzheimer’s and other neurodegenerative diseases? Could this mushroom help Parkinson’s patients or those with multiple sclerosis, or maybe maintain your mental acumen as you age? Lion’s mane is a relatively inexpensive, easily-cultivated fungal food that may prove to be therapeutic in ways beyond being tasty.
Lion’s mane may be our first “smart” mushroom. It is a safe, edible fungus that appears to confer cognitive benefits on our aging population. Unfortunately, lion’s mane is not available in most grocery stores. But you can buy kits to grow them at home, and organic lion’s mane supplements are available at some health food stores. If you are skilled enough and looking for adventure, you can forage for them by hunting in the hardwood forests of North America, Europe and Asia during the summer and fall.**
*Hedgehog is a name more commonly associated with Hydnum species, specifically the edible Hyndum repandum.
**Before consuming any wild mushroom, make positively sure that it is accurately identified. For a list of mycological societies, which may be able to help you, go to the North American Mycological Association website: www.namyco.org.
Kawagishi, H., Ando, M., Sakamoto, H., Yoshida S., Ojima, F., Ishiguro, Y., Ukai, N., Fukukawa, S. 1991. “Hericenone C, D and E, stimulators of nerve growth factor (NGF) synthesis from the mushroom Hericium erinaceum.” Tetrahedron Lett 32, 4561-4564.
Ma, Bing-Ji , Jin-Wen Shen, Hai-You Yu, Yuan Ruan, Ting-Ting Wu & Xu Zhao, 2010. “Hericenones and erinacines: stimulators of nerve growth factor (NGF) biosynthesis in Hericium erinaceus.” Mycology: An International Journal on Fungal Biology. 1(2): 92-98.
Mori, K., Inatomi, S., Ouchi, K. Azumi, Y and Tuchida T. 2009. “Improving effects of the mushroom Yamabushitake (Hericium erinaceus) on mild cognitive impairment: a double blinded, placebo controlled clinical trial.” Phytother Res. 23:367-372.
Mori, K., Obara, Y., Moriya, T., Inatomi, S., Nakahata, N. 2011. “Effects of Hericium erinaceus on amyloid β(25-35) peptide-induced learning and memory deficits in mice.” Biomed Res. 32(1):67-72.
Nagano, M., Shimizu, K., Kondo, R., Hayashi, C., Sato, D., Kitagawa, K., Ohnuki, K. 2010. “Reduction of depression and anxiety by 4 weeks Hericium erinaceus intake.” Biomed Res. 31(4):231-7.
A Single Dose of Psilocybin Mushrooms Can Reduce Anxiety for Nearly Five Years
By Chris Moore | News | January 14, 2020
A 2016 study found that a single dose of shrooms can significantly reduce cancer patients’ fear of death, and a new follow-up study has found that these benefits can last for years.
Nearly five years ago, a team of researchers conducted a landmark trial exploring whether psilocybin, the compound in magic mushrooms that makes us trip balls, could reduce anxiety in patients suffering from lethal forms of cancer. Since then, researchers’ interest in exploring the therapeutic potential of Psilocybe cubensis has skyrocketed.
Several clinical trials in the last half-decade have concluded that psilocybin can effectively treat anxiety, depression, and other conditions. That’s why the federal government is now seriously considering legalizing this natural psychedelic as an adjunct to therapy.
In the original 2016 study, researchers gave a single dose of psilocybin to 29 people suffering from life-threatening forms of cancer. Each of these patients was previously diagnosed with anxiety and/or depression as a direct result of their illness. Six months after taking this single dose, between 60 and 80 percent of patients reported a significant reduction in symptoms of depression and anxiety.
Years later, the original research team followed up with patients from the original study to see if the positivity generated from the psilocybin experience was still in effect. Out of the surviving 16 patients, 15 agreed to take additional psychological assessments between 3.2 and 4.5 years after the initial study.
“Reductions in anxiety, depression, hopelessness, demoralization, and death-anxiety were sustained at the first and second follow-ups,” the authors wrote in the follow-up study, published in the Journal of Pharmacology. At the second follow-up, 4.5 years after the original study, 60 to 80 percent of patients still showed signs of decreased anxiety and depression. “Participants overwhelmingly (71-100%) attributed positive life changes to the psilocybin-assisted therapy experience and rated it among the most personally meaningful and spiritually significant experiences of their lives.”
The authors also asked participants to describe how their psychedelic experience changed their outlook on life. “I experienced such overwhelming love in my psilocybin experience that it gave me new confidence,” one subject responded, according to IFLScience. “I think the extreme depth of love I felt changed the way I relate to others. [It] gave me a feeling that I have a right to be here and to enjoy life.”
Another participant said that “the psilocybin experience changed my thoughts about myself in the world… I see myself in a less limited way. I am more open to life. It has taken me out from under a big load of feelings and past issues in my life that I was carrying around.”
“These findings suggest that psilocybin-assisted psychotherapy holds promise in promoting long-term relief from cancer-related psychiatric distress,” the study concludes.
The authors note that the study does have its limitations, especially due to its small subject pool. But that doesn’t take away from the study’s positive implications. “Nonetheless, the present study adds to the emerging literature-base suggesting that psilocybin-facilitated therapy may enhance the psychological, emotional, and spiritual well-being of patients with life-threatening cancer.”
Johns Hopkins Scientists Give Psychedelics the Serious Treatment
The first research center of its kind in the country is bringing renewed rigor to the investigation of the drugs’ therapeutic uses
By Tanya Lewis on
Psychedelic drugs—once promising research subjects that were decades ago relegated to illicit experimentation in dorm rooms—have been steadily making their way back into the lab for a revamped 21st-century-style look. Scientists are rediscovering what many see as the substances’ astonishing therapeutic potential for a vast range of issues, from depression to drug addiction and acceptance of mortality. A frenzy of interest has captivated a new generation of researchers, aficionados and investors, triggering some understandable wariness over promises that may sound a little too good to be true. But late last year the highly respected institution Johns Hopkins University—the U.S.’s oldest research university—launched a dedicated center for psychedelic studies, the first of its kind in the country and perhaps the world’s largest. With work now underway, the center is aiming to enforce the strictest standards of scientific rigor on a field that many feel has veered uncomfortably close to mysticism and that has relied heavily on subjective reports. Early results have been promising and seem poised to keep the research on a roll.
Psilocybin (a psychoactive compound found in certain mushrooms) and LSD were widely studied in the 1950s and 1960s as treatments for alcoholism and other maladies. They later gained a reputation in the media and the public eye as dangerous and became strongly associated with the counterculture. Starting in 1966, several states banned their use. In 1968 LSD was outlawed nationwide, and in 1970 Congress passed the Controlled Substances Act, classifying that drug and psilocybin, along with several others, as having a high potential for abuse and no accepted medical use. But in recent years a rapidly growing number of studies reporting encouraging results in treating depression, addiction and post-traumatic stress disorder (PTSD) have brought them back out of the shadows, spurred on by positive media coverage.
In a major boost to the reviving field, Johns Hopkins’s Center for Psychedelic and Consciousness Research is exploring the use of psychedelics—primarily psilocybin—for problems ranging from smoking addiction to anorexia and Alzheimer’s disease. “One of the remarkably interesting features of working with psychedelics is they’re likely to have transdiagnostic applicability,” says Roland Griffiths, who heads the new facility and has led some of the most promising studies evaluating psilocybin for treating depression and alcoholism. The myriad applications suggested for these drugs may be a big part of what makes them sound, to many, like snake oil—but “the data [are] very compelling,” Griffiths says. And psychedelics may not only hold hope for treating mental disorders. As Griffiths puts it, they provide an opportunity to “peer into the basic neuroscience of how these drugs affect brain activity and worldview in a way that is ultimately very healthy.”
As author Michael Pollan chronicles in his 2018 best seller How to Change Your Mind, researchers were examining the therapeutic effects of psychedelics in the 1950s—a decade before then Harvard University psychologist Timothy Leary and his colleague Richard Alpert started their notorious study in which they gave psilocybin to students (ultimately leading to Leary’s and Alpert’s dismissal from the university). In the 1950s–1970s, studies conducted with LSD—which acts on the same brain receptors as psilocybin—reported strong results in treating substance use disorders, including alcohol and heroin addiction. But when LSD became illegal in 1968, funding for this work gradually dried up. Most psychedelics research stopped or went underground.
PSYCHEDELICS’ NEW WAVE
Griffiths and some of his colleagues helped revive the field around 2000, when they obtained government approval to give high doses of psilocybin to healthy volunteers. The researchers published a foundational study in 2006 showing a single dose was safe and could cause sustained positive effects and even “mystical experiences.” A decade later they published a randomized double-blind study showing psilocybin significantly decreased depression and anxiety in patients with life-threatening cancer. Each participant underwent two sessions (a high-dose one and a low-dose one) five weeks apart. Six months afterward, about 80 percent of the patients were still less clinically depressed and anxious than before the treatment. Some even said they had lost their fear of death.
Armed with these promising results, Griffiths and his colleagues turned their attention to other clinical applications. They decided to investigate tobacco addiction—in part because it is much easier to quantify than emotional or spiritual outcomes. Johns Hopkins researcher Matthew Johnson led a small pilot study in 2014 to see whether psilocybin could help people quit smoking. It was an open-label study, meaning the participants knew they were getting the drug and not a placebo.
The work followed a classic model for psychedelic therapy in which the participant lies on a couch and wears eyeshades while listening to music. Researchers do not talk to or guide subjects during the trip, but before each session, they do try to prepare people for what they might experience. In Johnson and his colleagues’ study, participants also underwent several weeks of cognitive-behavioral therapy (talk therapy aimed at changing patterns of thinking) before and after taking psilocybin. The drug was given in up to three sessions—one on the target quit date, another two weeks later and a third, optional one eight weeks afterward. The subjects returned to the lab for the next 10 weeks to have their breath and urine tested for evidence of smoking and came back for follow-up meetings six and 12 months after their target quit date.
At the six-month mark, 80 percent of smokers in the pilot study (12 out of 15) had abstained from cigarettes for at least a week, as verified by Breathalyzer and urine analysis—a vast improvement over other smoking cessation therapies, whose efficacy rates are typically less than 35 percent. In a follow-up paper, Johnson and his colleagues reported that 67 percent of participants were still abstinent 12 months after their quit date, and 60 percent of them had not smoked after 16 months or more. Additionally, more than 85 percent of the subjects rated their psilocybin trip as one of the five most meaningful and spiritually significant experiences of their lives. The team is currently more than halfway through a larger, five-year study of 80 people randomized to receive either psilocybin or a nicotine patch at the new Johns Hopkins center. Recruitment for the study is ongoing.
The exact brain mechanism by which the therapy appears to work remains unclear. At the psychological level, Johnson says, there is evidence that the sense of unity and mystical significance many people experience on psilocybin is associated with greater success in quitting, and those who take the drug may be better able to deal with cravings. At the biological level, he adds, scientists have hypothesized that psilocybin may alter communication in brain networks, possibly providing more top-down control over the organ’s reward system. A team led by Johns Hopkins cognitive neuroscientist Frederick Barrett is now investigating further by using functional magnetic resonance imaging to measure brain activity before and after patients undergo the therapy.
Like any drug, psilocybin comes with risks. People with psychotic disorders such as schizophrenia (or a strong predisposition for them) are generally advised against taking the hallucinogen. People with uncontrolled hypertension are advised to abstain as well, because psilocybin is known to raise blood pressure. Although it appears to be one of the safest “recreational” drugs and is not considered addictive, there have been reports associating it with deaths—but these may have been the result of multiple drugs, impure substances or underlying medical issues. In the smoking study, a third of participants experienced some fear or anxiety at a high dose of the psilocybin, Johnson says. But he adds that the risks can be minimized by carefully selecting participants and administering the drug in a controlled environment.
The smoking study results are promising, but Johnson says its relatively small size is a limitation. Also, subjects in such studies cannot comprise a completely random sample of the population, because it would be unethical to recruit people without telling them they may be taking a psychedelic drug. Thus, participants tend to be people who are open to this category of experience and, potentially, more apt to believe in its efficacy. And it is also hard to tease apart the effects of psilocybin from those of the cognitive-behavioral therapy in the smoking study, Johnson notes. He and his colleagues at the new center plan to conduct a double-blind, placebo-controlled study—the gold standard for medical investigations—in the future. Johns Hopkins researchers are also starting or planning studies using psilocybin therapy for a wide range of other conditions, including opioid addiction, PTSD, anorexia, post-treatment Lyme disease syndrome, Alzheimer’s disease and alcoholism in people with depression.
David Nichols, a professor emeritus of pharmacology at Purdue University, who was not involved in the recent Johns Hopkins studies but had synthesized the psilocybin used in Griffiths’s 2006 and 2016 papers, has been conducting research on psychedelics since the late 1960s. Back then, “you probably could have counted on one hand the number of people in the world that were working in this field. There wasn’t any money; there was no interest. [Psychedelics] were just looked at as drugs of abuse,” he says. Now “there’s a whole society set up to study these, with probably 150 international scientists working on it.”
Nichols says he has supported Griffiths’s and Johnson’s work since its early days, as they gathered the initial data that excited wealthy donors enough to fund the latest research. Philanthropic funding “is the way it’s going to be—until the National Institutes of Health decide that this is a field worth funding,” he says. “There are still too many political considerations that are keeping that from happening, but eventually, we’ll get there. We’ll get institutional support. We’re just not there yet.”
Psychedelic Events Are Going Mainstream, Where The Much-Maligned Mushroom Industry Focuses On Mental Health
Sara Brittany Somerset
Sara Brittany Somerset – Contributor – Forbes- Jan 12, 2020
Psychedelics have been a mainstay for a millennia and appreciated in the counter-culture for decades. In 2020, whether consuming, investing, or both, mushrooms are having a moment.
PsychedeliTech, a ground-breaking new conference, incubator and discovery platform for psychedelic medicine will host Rick Doblin, Ph.D., Founder and Executive Director of the Multidisciplinary Association for Psychedelic Studies (MAPS) as the keynote speaker at the first-ever PsyTech Summit, a forum for psychedelic science, innovation and investment conference, in Israel.
The inaugural PsyTech conference will take place March 29-30, 2020 at the Hilton Hotel, on the Mediterranean Sea in Tel Aviv.
PsyTech is a division of iCAN: Israel-Cannabis, which together with CannaTech, its medical cannabis events platform, has been a global participant in education and innovation for cannabis therapeutics and products with conferences in London, Sydney, Hong Kong, Panama and Cape Town, to date.
Saul Kaye, iCAN founder and CEO, said, “Rick Doblin is an early pioneer and extremely effective advocate for the potential of psychedelics in the treatment of mental health disease and symptoms, including depression, anxiety disorders, and PTSD. We are thrilled he will join us at our first PsyTech Summit in Tel Aviv to share his enlightened vision and vast knowledge of the fast-developing therapeutic ecosystem that is about to explode as a wave of new information, research and consumer interest about psychedelics floods the market.”
For the first 30 years of MAPS’ dedicated research, there were virtually no for-profit psychedelic business opportunities, apart from a few ibogaine and ayahuasca clinics and mushroom sales in countries where the substances are legal.
Psychedelics have the potential to impact and improve mental health.
For-profit entities emerging in the field of psychedelics, such as Cybin with microdosed psilocybin products and Mind Med with synthetic ibogaine, are directly due to the success of non-profit psychedelic therapy research, including the lifelong work of MAPS and other advocates.
Will Shroom Dispensaries Become a Thing Anytime Soon?
With the decriminalization of psilocybin, it’s hard not to wonder whether magic mushrooms will follow the path of cannabis.
Miro Tomoski – January 6, 2020
Imagine the sinking feeling that would barrel down your gut at the sight of DEA agents waiting at your door as you leave for work in the morning. Count the things they seized from your apartment: a notebook, an iPhone, a computer tower, a few graphic t-shirts, 906 live psilocybin mushrooms, and just over 20 ounces of dried shrooms. Late for your job in the legal cannabis industry, you begin to wonder what’s so bad about selling some homegrown medicine? After all, the city had just decriminalized psilocybin (the main psychoactive compound in magic mushrooms), and it’s only a matter of time before it’s sold in storefront shroomeries just like cannabis.
That is how Kole Milner spent one September morning, just five months after citizens voted in May of 2019 to decriminalize the possession of psilocybin mushrooms in his hometown of Denver. The agents never arrested Milner, though he knew exactly what he was doing: By his own admission he’d been selling psilocybin mushrooms, on a publicly accessible Venmo account—long before the Denver Psilocybin Initiative had them deemed the lowest level crime he could commit in the city. He had even told reporters at the Denver Post, NPR, VICE, and Westword what was growing mushrooms in his closet, while wearing a shirt branded with his own one-of-a-kind logo for a company called Happy Fox Edibles.
Even so, Milner still hasn’t been charged with a crime, despite having led law enforcement right into his living room. The investigation is still ongoing according to Jeff Dorschner, a spokesman for the US Attorney’s Office for the District of Colorado. This leaves open the possibility that Milner could face criminal charges, but his non-arrest in a city that now considers the possession of magic mushrooms to be a minor offense leaves us wondering when—if ever—psilocybin will be legal enough to sell.
“I believe it will be a long time until we see psilocybin dispensaries,” says Kevin Matthews, the architect of the ballot initiative that decriminalized psilocybin in Denver County last spring. “Anything is possible, but we have a tremendous amount of public education and data-collection to do before we can start having a serious dialogue about retail psilocybin.”
A synthetic version of psilocybin has already been granted “breakthrough therapy” status by the FDA to accelerate its route to market as a prescription medication for use in assisted-psychotherapy for depression. The nonprofit organization Usona and the for-profit company Compass Pathways are behind this drug development. Meanwhile, scientists at institutions like Johns Hopkins or New York University are also researching psilocybin for addiction, mysticism, anorexia, and various other applications.
The pharmaceutical model, with all its exclusivity, encourages people like Milner to continue growing mushrooms at home in order to avoid high price tags and to circumvent the need for a prescription, especially without a qualifying diagnosis. It may even push those who don’t qualify for the FDA-approved treatment to seek out people like Milner as caregivers to facilitate access to the psilocybin they need.
They started in Denver—and they’re taking the movement nationwide
Miro Tomoski – October 21, 2019
Kevin Matthews let out a laugh when asked if psilocybin—the primary psychoactive component in magic mushrooms—had ever helped him. “It saved my life,” he says. The former cadet had high hopes for his time at West Point, one of the world’s finest military academies, but service-related depression forced him to be honorably discharged. It wasn’t until he discovered psilocybin that he found relief—and was catapulted back into public service, but, this time, of a very different nature.
In May, Matthews led the nation’s first successful effort to decriminalize psilocybin in the county of Denver. Initiative 301, which made the use and possession of psilocybin the lowest priority for law enforcement, passed by a nail-biting margin of 50.6 percent to 49.4 percent. Now more than 90,000 Denver residents are counting on Matthews to make sure that their hard-won victory doesn’t end at the ballot box.
Always projecting one step ahead, Matthews had registered a nonprofit in Colorado a full year before the vote: the Society for Psychedelic Outreach, Reform, and Education. Otherwise known as SPORE, the group is considered to be the new psychedelic lobby—joining the ranks of other suits on Washington DC’s K Street who push for influence among the powerful.
“We’re not going to be lobbying, but we’re definitely going to be supporting groups and organizations that are doing that,” Matthews says. SPORE’s main focus is education, he adds, as well as filling in the gaps between what the voters want the law to look like and what policy is realistic in a world with competing interests. At the moment, SPORE is focused on ensuring that decriminalization works as it was intended to in Denver.
To many of us, drug legalization or decriminalization seems as if it should be rather straightforward. Voters cast their ballots, and the very next day they can no longer be arrested for possessing that substance. But while we’d all like to believe democracy is as simple as voting for or against something (or someone), each election day is often followed by a mad scramble of public officials, law enforcement, bureaucrats and business interests working behind the scenes to define the new normal.
When a previously illegal substance is added to that mix, a county like Denver becomes saddled with awestruck community leaders who now must grapple with something they’ve spent most of their lives avoiding. The best example we have of these behind-the-scenes negotiations has been the legalization of cannabis, forcing state officials all over the country to consider possession limits, retail licensing, zoning provisions, and other unprecedented questions around possession, sale, and production of the substance.
SPORE hopes to accelerate this process by coordinating with legal experts, medical professionals, and lawmakers in order to put these changes into practice in a way that’s faithful to what voters envisioned when they cast their ballots.
In Denver, the decriminalization process begins with a Psilocybin Policy Review Panel, which was written into Initiative 301 and includes members of city council, medical experts, law enforcement, and a representative of the team who wrote the initiative. The panel, which is expected to be formed by the end of October, is meant to ensure that the measure is implemented without restrictive roadblocks. (See Massachusetts which took more than two years to open a dispensary after voters legalized recreational cannabis.)
Having met with officials in the mayor’s office and twice with the District Attorney since election day, Matthews is now thinking about everything from roadside ads for responsible use to training first responders in harm reduction tactics. And that’s not to mention possession limits, which he hopes to eliminate entirely when it comes to personal use.
In essence, SPORE is Matthews’ attempt to give the people of his community exactly what they voted for—but it also offers assistance and expertise to anyone who’s looking to replicate Denver’s success across the country. The idea is to bring together proponents of decriminalization into one cohesive political force.
With the exception of cannabis, which has found unifying political voices in national organizations like NORML (the National Organization for the Reform of Marijuana Laws), DPA (the Drug Policy Alliance), and the Marijuana Policy Project, efforts to decriminalize other psychoactive substances have largely been organized on a local level. These grassroots activists have had to build their organizations from the ground up and rely on research-based evidence coming out of organizations like MAPS (the Multidisciplinary Association for Psychedelic Studies).
Among these individuals is Ryan Munevar, campaign director of Decriminalize California, who now faces the colossal task of convincing nearly 20 million registered voters throughout the state to turn out in support of psilocybin decriminalization. While the city of Oakland already passed an all-plant decriminalization measure, and while Denver has shown that an election can be won with a paper-thin margin, California is often feared as the most expensive state in which to run a political campaign. (Moreover, a 2018 attempt at a similar initiative failed to gather enough signatures.)
Matthews learned the same hard lessons when his first two petitions to put a decriminalization question on the ballot in November of 2018 were denied by elections officials in Denver before they even reached voters. But Munevar is still optimistic, having consulted with Matthews and drawn inspiration from his success.
“Honestly we might even be able to swing a lot of Republicans to our side,” Munever says, pointing out that right-leaning voters were a base of support for the Denver initiative. In fact, garnering support from more conservative voters could be another important part of SPORE’s mission. Where evidence from FDA-approved psilocybin research from institutions like Johns Hopkins provides the data to support decriminalization, SPORE could mobilize the electorate to vote for it.
By the end of the year, SPORE aims to conduct statewide polling in Colorado to determine how residents feel about psilocybin decriminalization on a larger scale. But for now, Matthews has focused his efforts on finishing what he started in Denver with an eye toward taking SPORE to Washington DC and creating a nationwide movement.
Just like any other successful lobby, from the NRA to the AARP, identifying voters who will show up for the cause is a crucial part of convincing Congress to act.
“It’s unlikely that Denver city councilors were going to wake up one morning and say ‘I think we really need to look at the therapeutic benefits of psilocybin’ without the voters telling them to do so,” says attorney Noah Potter, a legal advisor to the Decriminalize Denver campaign and founder of the New Amsterdam Psychedelic Law blog.
Potter calls this group of voters the “psychedelic constituency,” and the advantage is that they play on both sides of the political spectrum. That’s good news for SPORE because it means that voters who otherwise favor one party all the way down the ballot might stop to consider a decrim question.
“I’ll say it this way, we got endorsements from the Green Party and the Libertarian Party,” says Matthews, suggesting that folks with various political beliefs support decriminalization—at least in Colorado. “From our experience we’ve seen that people from all walks of life are interested in this.”
It also means that SPORE could have a wide base of donors to back their efforts. With an eye toward a national decriminalization campaign, they are currently applying for 501(c)(3) status with the IRS, which would allow them to collect donations as a charitable organization with the potential to one day become a 501(c)(4), or an organization that can take direct political action and receive unlimited anonymous donations.
Matthews wouldn’t be the first to take this route of activism—in fact, the Oregon Psilocybin Society has already been approved by the IRS under the 501(c)(3) category—but his national aspirations make SPORE unique.
“We intend to get in contact with federal policymakers and learn more about what each party is focused on in terms of psychedelics, whether it be economics or social justice,” Matthews tells DoubleBlind, expressing a bit of frustration with the current field of presidential candidates. “I want to see a drug policy debate during this election cycle.”
Still, while presidential hopefuls have so far kept their distance from the issue, New York Rep. Alexandria Ocasio-Cortez has not shied away and even tried to add an amendment to a broader government spending bill which would have made it easier to study psychedelics. “From the opioid crisis to psilocybin’s potential w/ PTSD, it’s well past time we take drug use out of criminal consideration + into medical consideration,” the freshman Congresswoman tweeted after introducing her amendment in June.
Her efforts were blocked by members of Congress, but the attempt showed that there is an appetite for reform among what Matthews calls the Psychedelic Caucus—a group of potential allies on Capitol Hill composed of AOC, as well as Democrat Reps. Rho Khanna and Lou Correa of California, and even Republican Rep. Matt Gaetz of Florida.
“Our victory in Denver was a clear indication that there is now a political foundation for the psychedelic renaissance,” Matthews says. And in the coming months, if SPORE is able to demonstrate that enough voters care about decriminalization, Denver could be just the beginning.